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GENERAL INTRODUCTION 
Introduction 
Glutamate is naturally present in almost all foods, 
including meat, fish, poultry, milk (human milk), and many 
vegetables. 
It occurs in bound form when linked with other amino 
acids to form proteins, and also in free form when it is not 
protien bound or in peptides. 
Therefore, protein rich foods such as human milk, cow's 
milk, cheese, and meat contain large amounts of bound 
glutamate, while most vegetables, including mushrooms, 
tomatoes and peas have high level of free glutamate. The 
glutamate content in foods is shown in table (1). 
The glutamate plays an important role in the natural 
and artificial ripening processes which is responsible for the 
development of taste in food. It is also used as an additive in 
processed food and hence the foods high in glutamate 
concentrations such as tomatoes cheese, and mushrooms, have 
gained key role in the popular cuisines of the world. For the 
vast majority of all known proteins, glutamate (MSG) is the 
major amino acid. As an essential link in intermediary 
metabolism it is also present in its free form in animal and plant 
tissues. 
Table. (1) Glutamate contents in Foods 
Food 
Cow's milk 
Human milk 
Camenbert 
Cheese 
Parmesan 
cheese 
Eggs 
Chicken 
Beef 
Pork 
Green Peas 
Sweet corn 
Tomatoes 
Spinach 
Protein in 
food<"^  (%) 
2.9 
1-1 
17.S-^ 
36.6*= 
12.8 
22.9 
18.4 
20.3 
7.4 
3.3 
0.7 
3.3 
GIu. in 
Protein 
(%) 
19.3 
15.5 
27.4 
27.4 
12.5 
16.1 
13.5 
15.7 
14.8 
15.1 
37.1 
9.1 
Protein-bound 
glutamate 
(g/lOOg)' 
0.560 
0.170 
4.787-^ 
9.847= 
1.600 
3.700 
2.500 
3.200 
1.100 
0.500 
0.260 
0.300 
Free^utamate 
(mg/lOOg) 
1-9*' 
2-2^ 
390"" 
noo-* 
23 = 
44^ 
33^ 
23*^ 
75g 
100'' 
246'' 
47h 
Sources: 
a- Resources council, science and Technology Agency, Japan (1986) 
b- Rassin et.al. (1978) 
c- The Glutamate Association 
d- Giacometti (1979) 
e- Maeda et.al. (1961) 
f- Maeda et.al. (1958) 
g- Suzuki et.al. (1976) 
h- Kiuchi and Kondo (1984) 
CHEMICAL PROPERTIES 
A. Structural Relationships 
Glutamate-Related Substances 
The L forms of a-amino dicarboxylates .that have four 
to seven carbons possess taste properties similar to that of 
L- glutamate (Fig I) Likevr^ise compounds that have the threo 
form and the hydroxy groups in the 3-position, such as DL-
threo-p-hydroxyglutamate (Fig. II), impart a more intese taste 
than those compounds that have the erythro form and the 
hydroxy group in the y-position. L-Homocystate (Fig. Ill), which 
has an SO.,H group in the y-position of the L-Glutamate 
molecule, also has the Umami taste, 
Other amino acid salts that have similar sensory 
properties are ibotenate (Fig. IV), tricholomate (Fig. V), and L-
threanine (Fig. VI); in contrast, a-methyl-L-Glutamate (Fig. 
VII), in vs^hich the a-hydrogen atom is substituted for a methyl 
group, is tasteless, and pyrrolidone carboxylic acid (Fig. VIII), 
v/hich is formed by the loss of water from the NH^ and y-COOH 
groups of L-Glutamate, has a sour taste (Kaneko, 1938). 
Stability-
(1) Glutamate is a non-hygroscopic and does not change in 
appearance or quality during storage. The characteristic 
taste of L-glutamate. (umami), is a function of its 
COONa 
CH, 
I 
H —C —NH, I 
COOH 
COONa 
HO —C —H 
I 
H —C—NH, 
1 • 
COOH 
OjNa 
H —C —NH, 
COOH 
( F i g . I ) L —Glutamale ( f i g . n)DL-threo — p —hydroxy- ( F i g . I l l ) L-Homoc>state 
Glulamale 
(IV) H,C — CH — CH —COONa 
1 1 1 
^C. p NH, 
O H 
( F i g . IV)L-ibotenate 
(IV) 
O 
H,C — CH — CH — COONa 
• I I 
O NH, 
H 
( F i g . V ) L-tricholomate 
CONHC,H, 
1 
CH, I -
CH, 
I 
H— C—NH 
I 
COOH 
(Fig. VI) L-theanine 
COONa 
CH, 
I 
r 
H3C—C—NH, 
COOH 
(Fig. VII) a-methyl-L-Glutamate 
H,C CH-
" I I 
.C CH—COONa 
H 
(Fig. VIII) L-Pyrrolidone carboxylate 
Figs. (I-VIII) Chemical Stractnres of Glutamate related substances 
stereochemical molecular structure. The D-isomer of 
glutamate does not possess a characteristic taste or 
enahance flavours (Yoshida, 1978). 
(2) Glutamate is not decomposed during normal food 
processing or in cooking. In acidic (pH 2.2-4.4) conditions 
with high temperatures, a portion of glutamate is 
dehydrated and converted into 5-pyrrolidone-2-carboxylafe 
(Yoshida, 1978). 
(3) At very high temperature, glutamate racemizes to DL-
glutamate in strong acid or alkaline conditions but 
especially in the latter. Maillard (or Browning reactions) 
occur when glutamate is treated at high temperatures with 
reducing sugars (Yoshida, 1978). 
Food Applications 
The major use of monosodium glutamate (MSG) in cooking 
around the world is as a flavour enhancer in soups and broths, 
sauces and gravies, and flavourings and spice blends. MSG is 
also included in a wide variety of canned and frozen meat 
poultry, vegetables, and combinatioin dishes. As MSG is readily 
soluble in water, it is dissolved in the aqueous ingredients of 
products such as salad dressings before they are added to food. 
Table:(2) Processed foods to which flavour enhancer 
(Glutamate) is added and its quantitative ranges. 
Food 
Canned Soups 
Canned asparagus 
Canned Crab 
Canned fish 
Canned poulty. Sausage harn fish 
Dressings 
Ketchup 
Mayonnaise 
Sausage 
Snacks 
Soy Sauce 
Vegetable juice 
Processed cheese 
Dehydrated Soufas 
Soup powder for instent noddles 
Sauces 
Quantitative ranges 
(Glutamate, %) 
0.12-0.18 
0.08-0.16 
0.07-0.10 
0.10-0.30 
0.10-0.20 
0.30-0.40 
0.15.0.30 
0.40.0.60 
0.30-0.50 
0.10-0.50 
0.30-0.60 
0.10-0.50 
0.40-0.50 
5-8 
10-17 
1.02-1.2 
Source : Maga (1983) 
Biochemical Aspects of Glutamate 
(1) Absorption and metabolism: Glutamate plays a vital role in 
the metabolism in the body. It is synthesized in the body to meet 
its demand (endogenecity) and is among those amino acids that 
are classified as nonessential. It is not necessary to supply these 
amino acids in the diet. However, the non-essential amino acids 
provide two-fold benefits to our well-being. They provide 
important sources of nitrogen and act to supplement or to 
conserve the essential amino acids, whose supply could 
otherwise be depleted. 
Glutamate is used by the organism for a wide variety 
of metabolic processes and plays an importent role in nitrogen 
and energy metabolism. 
The normal steps in the metabolism of glutamate 
include oxidative deamination, transamination, decarboxylation, 
and amidation. All are well established in mammals (Meister, 
1974). 
Blood-Brain Barrier: 
The free glutamate content of the brain is rather large 
in brain cells at rates commensurate with metabolic demand 
(Oldendorf, 1971). 
8 
Availability of amino acids to the brain is considered 
as a function of peripheral plasma concentration and blood-brain 
barrier (BBB) permeability. Although there is an exchange 
between plasma and brain glutamate, there is no net increase 
in brain glutamate levels after administration of a large amount 
of glutamate (Garattini, 1979). 
Pardridge also shows that the normal plasma glutamate 
level is nearly four times the K^ (0.04 mM) of the transport 
of glutamate to the brain; thus glutamate carriers to the brain 
are virtually saturated at physiological plasma levels of this 
amino acid. Furthermore, when rates of glutamate influx are 
compared to net glutamate release from brain, an active efflux 
system for glutamate appears to exist (net release is seven fold 
greater than the rate of influx) (Pardridge, 1979). 
The effects of glutamate administration on the 
glutamate concentration of the regional brain areas have been 
studied. 
The observed results indicate that blood-brain and blood-
retinal barriers are impermeable to glutamate except when massive 
doses (greater than2g/kg body weight of MSG dissolved in water 
to yield greater than 20-fold increase over normal plasma glutamate 
levels) or given to infant mice or rats (Liebschutz et. al. 1977). 
PJacental Barrier; 
Stegink has examined glutamate metabolites following 
infusion of radioactive MSG into pregnant monkeys. When MSG 
was infused at a constant rate of Ig/hr (equivalent to 0.16 - 0.22 
g/kg body weight), maternal plasma glutamate levels increased 
10-20 fold over baseline; fetal plasma glutamate levels, 
however, remained unchanged. During infusion, 60% of the 
radioactivity in the maternal circulation was in the form of 
glutamate. The major radioactive compounds detected in the 
fetal circulation were glucose and lactate. It indicates a rapid 
metabolism of MSG by the mother. However, there was 
essentially no sign of presence of labelled glutamate in fetal 
plasma. At higher rates of infusion, maternal plasma levels of 
glutamate rose to approximately 70 times while peak fetal plasma 
glutamate levels increased to less than 10 times than that of 
normal one (Stegink et. al., 1975). 
Schneider has studied the transfer of glutamate 
following an in vitro perfusion technique of the human placenta. 
When the fetal perfusate was recirculated, glutamate was 
progressively removed from the fetal circulation so that fetal 
concentrations fell below maternal concentrations (Schneider 
et.al., 1979). 
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Therefore, it can be concluded that the placenta serves 
as an effective barrier to the transfer of glutamatie by rapidly 
metabolizing it. 
Ebert (1979). and Owen et.al., (1978) conducted the 
experiment on MSG (monosudium-L-glutamate), monosodium-
DL-glutamate 
TOXICOLOGY 
(a) General toxicity 
(i) Acute and Chronic toxicity:-
The acute toxicities of glutamate are very low (Table). 
Apparent LDj^ values for the oral route are higher than those 
for the parenteral routes. 
Table (3); Acute Toxicity Studies of MSG in Mice & Rats. 
Species 
MICE 
RATS 
Route 
po 
sc 
jp 
iv 
po 
sc 
ip 
iv 
LD50 (g/kg body weight) 
Male Female 
17.7 
8.20 
6.57 
3.70 
17.3 
5.58 
5.70 
3.30 
15.4 
8.40 
5.70 
3.30 
15.8 
6.40 
4.80 
3.30 
Source: Moriyuki and Ichimura (1978) 
11 
and L-glutamic acid by adding these compounds to diets in 
various concentration levels and fed to mice, rats, or dogs for 
approximately 2 yrs. No evidence of carcinogenicity or specific 
adverse effects of these substances has been reported. 
(2) Reproduction and Multigenerational Studies 
In a large three-generation study carried out in mice 
fed diets containing 1% or 4% MSG, average intakes at 1% 
MSG concentration were between 1500 and 1800 mg/kg body 
weight per day (500-600 times the average daily human 
consumption of MSG). The intake of MSG in dams increased 
considerably in all groups during lactation. Nevertheless, the 
pre-and post-weaning performance of the young was unaffected 
(Anantharaman, 1979). 
In multigenerational studies including studies on 
reproductive performance, mice were fed diets containing various 
levels of MSG. These studies reported no advese afferts of 
MSG (Semprini et.al., 1974; Yonetani & Matsuzawa, 1978; 
Yonetain et.al., 1979). 
(3) Teratology: 
In studies investigating the teratogenicity of MSG, 
MPG and monoanimonimum glutamate in mice, rats, rabbits, 
or chicken embryos, these three substances were demonstrated to 
12 
have no teratogenic effects under any of the experimental 
conditions used (Food & Drug Research, 1974aib. 
Mutagencity: 
Glutamates were tested for genotoxicity in a series of 
Ames tests with and without metabolic activation on Ames tests. 
Neither aberration tests in a Chinese hamster fibroblast 
cell live (Ishidate et.al., 1984) no host mediated assay in rats 
(Industrial Biotest laboratories 1973) showed any mutagenic 
effects. 
B. Special toxicity: 
Special studies on brain lesions in sensitive animal 
species, utilizing the injection or forced feeding of a huge dose 
of MSG in high concentrations indicate that glutamate like other 
components, can induce toxic effects in test animals. However, 
the levels required to induce toxicity represent amounts and 
non-dietary methods of administration not experienced by 
humans. When a huge amount of glutamate is given to a test 
animal species following the same rates, routes , and 
concentrations as used by humans, no toxic effcts are seen even 
in the most sensitive animal species (Takasaki, 1978 a. 1978b). 
In studies done on mice using huge dose levels (500 
mg/kg body weight) (Olney, 1969; Olney & Ho, 1970; Olney 
13 
et.al. 1972; Lemkey-Johston and Reynolds, 1972), MSG was 
shown to produce brain lesion when the compound was injected 
or administered by forced incubation. Treatment of more with 
MSG by non dietary routes of administration, that is, injection 
or forced incubation, resulted in sufficiently high blood 
glutamate levels to apparently force enough MSG into the brain 
to induce toxicity (O'hara and Takasaki, 1979). 
In mice, the heav>' doses of dietary feeding of MSG 
than human being, (over 12,000 times its maximum anticipated 
levels of use in humans) was without toxic effects to the brain. 
Nondietary routes of administration viz; subcutaneous injection 
or oral forced feeding, were required to induce toxic effects even 
in highly susceptible fetal, new born and young rodents (O'hara 
et.al., 1977; O'hara and Takasaki, 1979; Takasaki, 1979; Daabees 
et.al. 1984; Anantharaman, 1979). 
Five independent laboratories found that the monkey 
show no brain damage following the injections of huge amounts 
of MSG in high concentrations. Even the direct injection to 
the fetus did not cause lesions in the hypothalamus (Abraham 
et.al., 1975; Stegink et.al., 1975; Heywood and Worden 1979; 
Reynolds et. al, 1976, 1979). 
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C. Observations in humans: 
An anecdotal report in 1968 triggered curiosity about 
the so-called Chinese restaurant syndrome (CRS), which was 
associated with transient subjective symptoms of burning, 
numbress and a tight sensation in the upper part of the body, 
reportedly after a meal in a Chinese restaurant (Kwok, 1968). 
It was suggested to have some possible association with food 
ingredients such as MSG (Schaumburg et.al., 1969). No 
objective changes in skin temperature, heart rate, ECG, or 
number tone were observed, and no correlation between plasma 
glutamate levels and symptoms was reported. The symptoms are 
mild, self-limited, and transient, occur 15-20 minutes after 
ingestion of a meal and disappear within 1-2 hr. with no sequelae 
(Kenney and Tidball, 1972; Stegink et.al. 1979). For assessment 
of the relevance of this kind of subjective reaction, experimental 
conditions without double blind techniques are not suitable 
(Zanda et.al., 1973). Quite a few double blind placebo-controlled 
clinical investigations were done and concluded that there was 
no correlatioin between MSG added and post prandial claims 
(Marrs et.al., 1978; Tung and Tung, 1980; Byung, 1980; Gore 
and Salman, 1980; Kenney, 1986). Kenney suggested that the 
symptoms arise from initiation of the upper oesophagus, and as 
the conentration is more important than dose, it was unlikely 
15 
to have these symptoms with the usual level of concentraton of 
glutamate added to food. He further demonstrated that orange 
juice, coffee, and spiced tomatojuice triggered some kind of 
sensations and suggested that "perhaps the CRS is no more than 
a manifestation of a common low-grade oesophagitis brought on 
by American dietary habits" (Kenney, 1980). 
An epidemiological or survey reports using a questionnaire 
approach were done by Kerr who made a survey and analyzed 
3222 answers. There were no definite CRS" or "probable CRS", 
and only 1.8% of people had over experienced "possible CRS". 
It was found that only 0.19% of the people reputed CRS-like 
symptoms after a meal in Chinese restaurant (Kerr et.al., 1979). 
disease outbreak records collected by the centres for Disease 
control showed only 0-3 outbreaks in the united states as a 
whole. 
Kenney challenged self-claimed CRS sufferers with MSG 
in a double blind clinical test. Six subjects who were convinced 
that they reacted to MSG, were given on four separate days 
either a soft drink solution that contianed 6 g of MSG or a 
placebo. Four showed no symptoms with either MSG or placebo, 
the other two experienced mild CRS to MSG as well as placebo 
(Kenney, 1986). 
16 
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Introduction 
Toxicology is considered to be a very recently developed 
scientific discipline. On the contrary, observations of harmful 
effects of chemical substances on living organisms is rooted in 
pre-history. Even the ancient people sought antidotes for poisons. 
Pre-historic humans, in their constant search for food, 
observed that certain fruits, berries, or roots had an injurious 
rather than a nourishing effect. Similarly, it was noted that the 
bite of some insects or reptiles was like-wise followed by severe 
illness or even death. Attempts to cure ailments probably led to 
still further experimentation with plants and minerals, some of 
which were found to produce harmful results even in healthy 
persons. 
While mankind's original quest was for food and other 
materials of beneficial nature some of which are having bitter 
historical experiences and 'Excitatory Amino Acids' is one such 
example. 
Excitatory amino acids were used as flavouring agents 
for foods which later on proved to be an addition in the bitter 
experiences in the way of mankind's original quest for food 
and other materials of a beneficial nature when Lucas and 
22 
Newhouse (1957) made observations on the cytotoxic effects 
of systemically administered Glu on the retina of neonatal mice 
by virtue of which 'Excitotoxic Lesion Technique' was developed. 
They observed that administration of Glu on the normal neonatal 
mice caused an acute degeneration revealed that neurons with 
cell bodies in the arcuate nucleus and in the circumventricular 
organs (CVO), which lie outside the blood brain barrier (BBB), 
were also vulnerable to the cytotoxic effects of systemically 
administered Glu in the neonatal rodent (Olney, 1969). 
Afterwards, Olney, by the dint of his studies conducted on 
the excitatory amino acids, concluded that the neurotoxic effects 
of a variety of acidic amino acids resulted from their 
depolarising action, which caused influx of sodium and water 
into the dendrites bearing their receptors. Thus, he coined the 
term 'excitotoxins' for these substances that appear to kill 
neurons on the basis of their excitatory effects (Olney, 1974). 
The current status of Glu. as a neurotoxin is still 
obscured by the variations of laboratories. By far, the most 
extensive use of Glu. is as an ablative or provocative tool in 
endocrinology. 
Neuronal cell bodies of the arcuate nucleus of the 
hypthalamus of infant rodents degenerated after systemic 
administration of MSG. The lowest effective doses are found 
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to be 0.5g/kg (oral) and 0.35 g/kg (subcutaneous) in 10 days 
old mice. Optimal parenteral doses (2-5g/kg, repeated every 48 
hr. until day 10 after birth) result in the destructioin of 80-90% 
of all local neuronal somata. 
Both light and electron microscopic examinations 
indicate a severe reduction of arcuate neurons within hours after 
MSG treatment. The subfornical organ and the area ostrema are 
also very susceptible to MSG, showing identical 'axon-sparing' 
lesions in response to the toxin (Olney, 1979), while other 
hypothalamic areas exhibit some degree of vulnerability vis-a-
vis MSG, extrahypothalamic brain regions: The cinguate cortex 
(Rascher, 1981) appear to be unaffected even by repeated 
administration of very high doses of MSG. Importantly, 
parenteral MSG also results in hypothalamic damage in adult 
rodents. 
The arcuate nucleus has long been known to constitute 
an essential relay station in the modulation of neuroendocrine 
functions (Weindt 1973) It was, therefore, not unexpected that 
destruction of arcuate cells would produce severe deficits in 
various hormonal systems. Adult animals treated with MSG 
during pregnancy indeed show reduced content of growth 
hormone levels and elevated serum prolactin levels (Nemeroff 
et al. 1977a and b). The latter, however, can be together with 
24 
decrease in gonadal size, indicates marked disturbances in sex-
hormonal status in both male and female rodents (Holywarth-
McBride et.al., 1976. Pizzi et al., 1977). Moreover, the weight 
of the anterior pituitary appears to be reduced in MSG treated 
rats when compared to age and sex-matched controls (Bakke 
et.al. 1978). while the affect on adrenal weight in animals 
exposed to MSG is controversial, plasma corticosterone levels 
in mice and female rats are dramatically increased (Olney, 1979). 
Finally, these exhibit pronounced histological changes in the 
thyroid glands of MSG treated mice that are indicative of 
hypothyroidism and these findings are corroborated by a 
significant reduction of both serum tri-iodothyronine and the free 
thyroxine index (Nemeroff et.al. 1977b Dhindsa et. al. 1981). 
Domoate, an analogue of kainate obtained from a 
marine plant, is more potent than kainate in electrophysiological 
tests and binding assays has recently been shown to have caused 
an outbreak of acute neurological disorder viz. amnesia in 
subjects consuming blue mussels (Perl, 1990; Teitelbaum, 1990). 
This is the only well documented incident in humans, in which 
a dietary toxin has caused an acute neurological degeneration 
apparently through a direct excitotoxic mechanism. A 
subcutaneous excitotoxic mechanism may be involved in 
neurolethyrism (Nunn et.al. 1987) involving dietary consumption 
of ingredients such as P-oxalyl-a,P-diamino propionic acid 
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(BOAA) and Guam-Amyotrophic Lateral Sclerosis-Parkinsonisra 
and dementia complex in people who consume the cycadnut, that 
contains Glu.-analogue p-N-methylamino-L-alanine (BMAA). 
Indirect excitotoxic effects can produce selective neurotoxicity 
e . g . , l - m e t h y l - 4 - p h e n y l - l , 2 , 3 , 6 - t e t r a h y d r o p y r i d i n e ( M P T P ) 
producing nigrostriatal pathology and 3-nitropropionic acid 
producing striatal pathology. Concern has frequently been 
expressed that dietary consumption of Glu. itself, (aspartate in 
the form of sweetener aspartame) or other structural and 
functional Glu.-analogues might be sufficient to produce damage 
to periventricular organs (Olney et.al. 1972). 
Both neonatal and adult animals are vulnerable to Glu-
induced brain damage but it requires higher systematic doses to 
damage the brain in adulthood (Olney, 1969, Lemkey-Johnston 
and Reynolds, 1972; Olney, 1976) while the basis for this 
remains to be determined, it is noteworthy that the same brain 
regions are preferentially affected at either age (Olney. 1969, 
1976). By ultrastructural analysis, Glu.-lesions in brain (Olney, 
1971; Olney et.al. 1971; Olney et al. 1977) regardless of species, 
involve rapid swelling of neuronal dendrites and cell bodies 
followed by nuclear chromatin. Because axons exhibit no 
degenerative changes in the acute period while signs of severe 
toxic reaction are evident in other neuronal compartments, this 
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has been termed as dendrosomatotoxic but axon sparing type of 
cytopathology 
Intracellular and extracellular compartments of Glu. 
The extracellular concentration of Glu in the Central 
Nervous System (CNS) is about ten thousand folds lower than 
that of intracellular levels (5|aM/Vs 50 mM). This is important 
for two reasons: 
(1) Glutamate(MSG)is the premier excitatory neurotransmitter 
and its low levels in the synaptic cleft amplifies the signal 
to noise ratio upon release of this amino acid from pre-
synaptic terminals and, 
(2) Excessive stimulation of certain glutamaterigic neurons, 
particularly those bearing a specific subtype of Glu.-
receptor viz., NMDA recptors can lead to neuronal injury 
and/or death ("excitotoxicity"). 
Under resting conditions, the Glu. concentrations in 
the extracellular space, the presynaptic cytoplasm and the lumen 
of glutamatergic synaptic vesicles are of the order of IjiM, 
lOuM, lOOmM, respectively. These gradients are maintained by 
two distinct electrogenic carriers. The acidic amino acid carriers 
present in the (a) presynaptic and (b) glial plasma membranes 
are Na--dependent, show a high (50|iM) affinity for Glu. and 
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does not transport aspartate. There is still controversy 
concerning the precise stoichiometrics of these carriers. 
Glutamate is normally released by Ca-^-dependent 
exocytosis, Earlier ambiguities concerning vesicular versus 
cytoplasmic release were due to difficulties in detecting the very 
labile storage of the amino acid within synaptic vesicles 
(Nicholls, 1989). 
However, the plasma membrane Glu. carriers may 
reverse their operation, releasing Glu into the extracellular 
space, if the Na^ and/or K"-gradients are chronically decreased. 
Glutamate may be reaccumulated directly into the 
nerve terminal or into adjacent glia. Glutamate synthetase(s) is 
predominantly glial and some glutamine can be formed from 
accumulated Glu. in this compartment. Glutamine is present at 
about 0.5 mM in the extracellular space and can enter the 
terminal by a low affinity Na^ in dependent pathway. (f) 
Glutamine may serve as a precursor for presynaptic cytoplasmic 
Glu through the mitochondrial glutaminase. (g) However, this 
enzyme is subjected to potent product inhibition by Glu. itself 
and it is unclear what contribution this enzyme makes to the 
resynthesis of transmitter glutamate (Mc Mohan et.al., 1990). 
Glutamate participates in an almost bewildening number of 
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metabolic reactions, many of which represent key 'switching 
points' in brain metabolism. 
Interconversion of Glutamate and a-ketoglutaric acid: Connection 
to carbohydrate metabolism and detoxification of ammonia. 
There are two reactions which bring about inter-
conversion of glutamic acid into a-ketogluterate, a compound of 
the tricarboxylic acid cycle. The reactions thus represent 
interchange poin ts between carbohydrates and protein 
metabolism. Their importance and rapidity are emphasized by the 
observation that 20 minutes following injection of "^C glucose, 
a large fraction of its radioactivity had been transferred to Glu. 
Two enzymes catalyze this reaction glutamate dehydrogenase and 
transaminase (za). Even though they catalyze reactions between 
the same compounds, the glutamate dehydrogenases and 
transaminases are separate enzymes; with distinct intracellular 
localization, functioin and co-factor requirements. 
The important enzymes involved in Glu. metabolism in 
the CNS are fumarate dehydnegenase and amino transferases, 
glutamine sysnthetases and phosphate activated glutaminase. In 
general, these enzymes are thought not to be specifically 
associated with neurotransmitter synthesis, because no clear 
distinction can be made between the participation of these 
enzymes in the metabolism of the transmitter-related and non-
transmitter related roots of Glu. (Schousboe and Hertz, 1983). 
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Glutamate Dehydrogenase (GDH:E.C.1.4.1.2) 
Substantial amounts of GDH activity are known to be 
present in mammalian brain (Williamson et.al. 1967; Cooper 
et.al. 1985). 
Brain GDH is an oligomer composed of several 
subunits (Subunit MWt. 56K). Glutamate dehydrogenase 
catalyzes either the reductive amination (RA) of a-ketoglutarate 
to Glu or oxidative deamination (OD\of glu to a-ketoglutarate 
COOH COOH 
CH-NH. C = 0 
(CH,), + NAD^ 4- H,0 < g o ^ ( W , + NH,^ + NADH + H^ 
L-Glutamate a-Ketoglutarate 
GDH is located in mitochondria (Salganicoff and de Robert, 
1965) preferentially in their matrix as a soluble enzyme (Mac 
Donnel and Greengard, 1974; Lai et.al., 1986]. 
Aspartate Aminotransferase (AAT; GOT; E.C.2.6.1.1.) 
AAT is one of the most active aminotransferase enzymes 
in brain (Benuck et.al. 1972). 
AAT catalyzes the reversible trans amination between 
L-Aspartate and a-Ketoglutarate to yield L-glulamate and 
oxaloacetate. 
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AAT is localized in the brain in the form of two 
isoenzymes with a cytosolic (AAT) and mitochondrial (mAAT) 
localization (Salganicoff and Robertis, 1965). 
Alanine Aminotransferases (ALAT; GPT; E .C. 2.6.1.2 
ALAT catalyzes the reversible process which mediates 
transfer of the amino group between glutamate and alanine. 
COOH 
1 
CH-NH, CH, 
1 ^ 
1 
- 1 
COOH COO" 
-Glutamate Pyruvate 
GPT 
CR 
1 ' 
^CH-NH 
1^ ' 
COOH 
Alanine 
COOH 
1 1 
c=o 
1 (CH,), 
COOH 
a-Ketoglutarate 
This enzyme is distributed relatively evenly among 
various regions of the CNS, the offence being 2.5 fold between 
the highest activity in cortical grey matter and lowest in corpus 
collosum (Benuck et.al. , 1972). It is present both in cytoslic and 
mitochondrial fractions of brain cells. 
Lactate Dehydrogenase (LDH) (E.C.I.1.1.27) 
The enzyme catalyzes the reversible reduction of 
pyruvate, and has been shown to exist in time genetically distinct 
molecular forms in mammals (isoenzymes). 
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They differ in their catalytic and immunological 
properties, amino acid composition and physical characteristics, 
though they have similar molecular weights 
I I ^  
C = 0 + NADH" + H- > CHOH+NAD* 
1 _ 1 
COO COO-
Pyruvate Lactate 
It is present in the cytoplasm and is used as a marker 
for measuring cell damage. 
Apart from the above mentioned enzymes, there are a 
number of other enzymes which are associated to the process of 
myelination and are sensitive towards any toxic exposure as reported 
earlier (Gietzen and Wooley, 1984; Gupta et.al. 1985; Blaker et.al. 
1981; Ohki et.al. 1985; Kung et.al. 1998; Riedel and Christensen 
1979; Rajanna et.al. 1983; Chetty et.al. 1992; Cooper et.al. 1984). 
These enzymes are Na^,K* Adenosine triphosphatase 
(Na^,K+ATPase), 5'-nucleotidase(5'-N), 2,3'- cyclic nucleotide-3'-
phosphohydrolase (CNPase), and Acetylcholinesterase (AChE). 
Moreover, there are several mitochondrial enzymes viz., succinate 
dehydrogenase (SDH), malate dehydrogenase (MDH),diapharose and 
thymidine kinase have also been shown to be sensitive towards toxic 
exposures as reported earlier (Vallee and Ulmer 1972; Babitch 1988; 
Fujioka and Lieberman 1964). Furthermore, there are a number of 
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antioxidant enzymes viz., glutathione reductase (GR) Gluthione 
peroxidase (GPx), superoxidase dismutase and catalase play an 
important role in due course of and after the toxic exposures as 
reported earlier (Sugawara and Sugawara 1991; Shukla et.al. 1988 a,b 
and c; Jamall and Smith 1985; Gill et.al. 1990, Manca et.al. 1990). 
It is interesting to note that j3-glucoronidase, a neurotoxic marker is 
also important from the view point of the present study. 
Brain lipids 
Among various body organs, the brain is one of the 
richest in lipids. Studies of lipids in the nervous system, are 
therefore, a vital part of the neurochemical investigations due 
to the immense importance of lipids in the brain, both as 
structural constituents and as participants in the functional 
activity of the brain. Lipids account for about half the dry weight 
and most of the structural architecture of membranes in the brain 
(Brante, 1949; Ordy and Kaask, 1975; Suzuki, 1981). Brain 
contains a unique structure, the myelin sheath, which has the 
highest lipid concentration of any normal tissue or subcellular 
components, except for adipose tissue. Total lipids make up 
about 65% of the dry weight of white matter and 35-40% of 
the gray matter (Brante, 1949). Myelin sheath contians about 
65% of the lipids of whole white matter. Myelin is present in 
all parts of the CNS, but is more concentrated in areas 
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composed mainly of fiber tracts, such as the white matter of 
brain and spinal cord and in peripheral nerves, such as sciatic 
nerve. Different types of membranes accumulate different types 
of lipids (Horrocks et.al. 1975). There is increasing evidence 
that lipid molecules play important functioinal roles within the 
membranes. Some of the postulated physiological functions of 
membrane lipids include the site for the cell-to-cell recognition 
process, specific cell-surface antigens, and specific receptors for 
toxins or other physiological compounds. 
The lipid composition of the brain is relatively stable 
throughout adult life. However, substantial changes in lipid 
composition take place during active myelination, the brain 
looses water, predominately in white matter, the lipid contents 
inreases rapidly and the difference between gray and white 
matter becomes more apparent (Wells and Dittmer, 1967; Norton-
& Poduslo, 1973). The rapidly increased myelin content is 
related with increase in brain weight (Smith et.al. 1983). 
Cumings (1955) compared the lipids of demyelinated lesions in 
multiple sclerosis with those of normal areas of the brain and 
found a decrease in sphingomyelin, cerebroside and free 
cholesterol sphingomyelin, cerebroside and free cholesterol. 
Phosphoglycerides, Cholesterol and galacto-lipids are present in 
natural myelin sheath, with the ratio of 3:4:2 respectively. 
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Gangliosides are localized primarily in plasma membranes 
(Karpova, 1978) but monosialogangliosides is present in limited 
quantity in myelin fractions (White et al. 1978). 
Most of the membrane lipids exist in a "bilayer form" 
according to "Fluid Mosaic" model of Singer and Nicolson 
(1972). The physical state of the lipid plays a critical role in 
directing the conformation and function of the membranes. The 
lipid layers of the membranes is predominantly composed of 
phospholipids and variable amounts of cholesterol and 
glycolipids (Tanford, 1978). 
Phospholipods 
Phospholipids are the primary lipid components of 
plama membranes, organs membranes and myelin membranes. 
The importance of these phosphorus containing lipids in the CNS 
presumably depends upon their role as membrane constituents. 
Phospholipids constitute approximately one-fourth of the dry 
weight of brain (White, 1973). They account for 4 . 1 % of fresh 
weight and 22.7% of dry weight of the gray matter, and 7.2% 
of fresh weight and 25.2% of dry weight of the white matter 
(Suzuki, 1981). The lipids of mammalian CNS myelin are 
composed of 4.6% phospholipids and hence it is proposed that 
phospholipids are the characteristic components of myelin sheath 
(Fumagalli and Paoletti , 1963). The metabolically active 
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phosphoinositides are located in the existable membrane of the 
neuron, particularly in the axolemma. Phospholipids not only 
constitute the backbone of biomembrane but also provide the 
membrane with a suitable environment, turbidity and ion 
permeability. Porcellati (1983) reported that different 
phospholipids turnover at different rates with respect to their 
structure and localization in various cells and membranes. 
Newly synthesized phospholipids are transported to membranous 
structures by phospholipid exchange and transfer proteins 
(Demel et.ai. 1984) which are found in the cytosol. The 
distribution of phospholipids in biological membranes is thus 
regulated not only by the activities of enzymes involved in their 
metabolism but also by the transport and incorporation processes 
into the membrane. Metabolic pathways of phospholipids in 
brain are similar to those in systemic organs (Rossiter, 1966) 
and are depicted in Fig (1) 
Cholesterol: 
Cholesterol is widely distributed in other body organs, 
and is found in the highest concentration within the central and 
peripheral nervous systems. Cholesterol accounts for about 10% 
of dry weight of the brain as compared to less than 1% found 
in most of the other organs. Unesterified cholesterol has been 
suggested as a lipid characteristic of myelin sheath, as it occurs 
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in white matter in a higher concentration than in gray matter 
(Johnson, 1969; Brantes 1949). Cholesterol constitutes 
approximately 25% of myelin lipid by eight (Soto et.al. 1966) 
and about 70% of total brain cholesterol is present in myelin 
(Leatsch et.al. 1962). Cholesterol is thought to act as a conveyer 
in the absorption of fats. Bloor (1943) reported a parallelism 
between cholesterol content of blood and the fatty acids. Due 
to the abundance of cholesterol in nervous tissue and its 
variation in mental diseases, it may function as an insulating 
medium for myelin sheaths. Adams (1961) indicated a strong 
reaction in the myelin sheath of peripheral nerve and the fibre 
tracts of the brain. Sterols are thought to have a role in 
maintaining the balance between the cell permeability and the 
membrane eqiiilibiiun) of living cells. Paoletti (1971) has 
described microsoiirccs as that subcellular site of cholesterol 
biosynthesis in brain. Cholesterol biosynthesis takes place in the 
brain through the same pathway as in the systemic organs 
(Suzuki 1981). Acetate and its pressuors are transformed 
through nevalanic acid to cholesterol as depicted in fig(3) 
Demosterol, the immediate precursor of cholerterol, is 
known to be present in brain in measurable amounts just prior 
to myelination (Smith et.al. 1967). Biosynthesis of cholesterol 
m brain is most rapid during active myelnation, but adult brain 
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retains the capacity to synthesize the cholesterol when 
precursors, such as acetate or nevalonate are available. 
Triglycerides: 
Triglycerides, or triacylglycerols, are fatty acid esters 
of glycerol, those found in humans usually containing a mixture 
of 2 or 3 different fatty acids, Stereospecific analysis shows that 
palmitic acid preferentially occupies the 1-position in the 
molecule, linoleic acid the 2-position, and oleic acid the 3-
position. 
Plasma triglycerides are absorbed mainly in the form 
of chylomicrons which traverse the intestinal lymphatics and 
enter the systemic circulation via the thoracic duct, in contrast, 
short or medium chain triglycerides, containing fatty acids with 
10 or less carbon atoms, are absorbed via the portal vein 
(Isselbacher, 1965). Normally, over 90 per cent of dietary 
triglyceride is absorbed, which means that roughly 80-170 
mmoles (70-150 g) of exogenous triglyceride enters the 
circulation per day. Triglycerides derived from endogenous fatty 
acid also originate int he small intestine but their chief source 
is the liver, whence they are secreted in the form of very low 
density lipoproteins (VLDL). The fatty acid pattern of 
triglycerides in both chlomicrons and in VLDL is markedly 
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influenced by the fatty acid composition of dietary triglyceride, 
under circumstances where the linoleic acid content of dietary 
triglyceride is inadequate by virtue of which essential fatty acid 
deficiency can occur (Press et al., 1974). 
Triglycerides have a relatively short half-life in plasma 
and are removed by a process involving hydrolysis and uptake 
by various organs, notably adipose tissue. These events are 
mediated by lipolytic enzymes. Triglyceride levels remain 
elevated for several hours after ingestioin of a fatty meal but 
normally all exogenous (chylomicron) triglyceride should have 
been cleared within 12 hours. Thus measurement of plasma 
levels in the fasting state reflects the amount of endogenous 
triglyceride in the circulation. Normal values for adult males 
range from 0.5 to 2 mmol/litre and up to 1.5 mmol/litre in 
premenopausal females. 
The brain is unique in its lack of certain lipids that 
are abundantly present elsewhere in the body. Triglycerides and 
free fatty acids constitute, at the most only a few percent of 
the total lipid of the brain (Suzuki, K., 1981). 
Gangliosides 
Gangliosides are defined as sialic acid containing 
sphingoglycolipids. Sialic acid is the generic name for N-acetyl 
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neuraminic acid, and the acyl group of sialic acid in the human 
brain is always the acetyle form (Suzuki, 1981). N-acetyl 
neuraminic acid is commonly abbreviated as Neu NAc Fig (4). 
The series of gangliosides in the brain has the ceramide 
oligohexides as the backbone, with one or more Neu-NAC 
moieties attached. Major gangliosides of the brain are GMj, GM2, 
GM3,GDLa, DDlb GT, Several other minor gangliosides have 
been identified in the nervous system, including GD^,GD^, and 
sialylgalactosylceramide. Gangliosides are the essential 
constituents of the cell membrane. They are more concentrated 
in the CNS than in other body organs (Svennerholm, 1980; 
Rahman, 1983). In the gray matter, 6% of the total lipids are 
gangliosides ( Lehninger, 1984). Also, gray matter contains many 
times higher ganglioside concentration, compared to white matter 
(Wolfe, 1972), Moreover, at the cellular level in the brain, 
ganglosides are more highly concentrated in numerous glial cells 
and nyjelm (Roberts, 1975; Ledeen, 1978; Yu and Iqbal, 1979) 
Regional differences in ganglioside patterns of the nervous 
system have also been recognized. In adult nervous system, the 
individual gangliosides have been suggested to play a role as 
membrane bound receptors or co-receptors for toxins, drugs, 
viruses, hormones, transmitters etc. (Svennerholm, 1980). 
Although no convincing evidence is available linking 
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gangliosides lo specific neuronal function, they may be involved 
in synaptic transmission (Raharaan et.al. 1982), owing to their 
binding capacity for calcium (Probst et.al. 1979) and 
transmitters (Richdardson et.al. 1982). 
Brain gangliosides are biosynthesized by sequential 
additions of monosacharides or Neu NAc to the carbohydrate 
starting from ceramide (Fig 4) (Kaufman et.al. 1967, Ledeen & 
Mellanby 1977). The biosynthetic steps are catalyzed by either 
sialyl or glycosyl transferases that are generally specific for the 
respective reactions. Although the bulk of the synthetic activities 
are localized in the microsomal fraction, there is evidence to 
suggest that some gangliosides sialyltransferase may also be 
present in nerve endings (Suzuki, 1981). Degradation of brain 
gangliosides also proceeds by sequential removal of 
monosaccharide and NeuNAc (Fig.3) by glycosidases and 
neuroaminidases (Ladeen and Yu, 1973; Ladeen and Mellenby, 
1977). Most of these hydrolytic enzymes are localized in 
lysosomes, where the catabolic processes of cellular constituents 
are believed to occur (Sandhoff and Christmanoue, 1979). 
Because of the high concentration in the neuronal 
membrane (Ledeen 1978) and the usual chemical structure of 
both hydrophilic and hydrophobic chains, the physiological 
functions of brain gangliosides, such as their static role as 
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membrane constituents, and their possible involvement in ion transport 
and nerve transmission, have been the subject of speculation. GMl 
can affect neurotransmitter receptors with a modulatory action observed 
on cortical 5-HT receptors (Agnati et.al. 1983). Gangliosides have also 
been shown to modulate the phosphorylation system (Agnati et.al. 
1984, 1985; Bremer et.al. 1986). 
Oxygen free Radicals and the Brain 
There has been intense interest in understanding the 
roles of oxygen radicals in biological systems, Much of the work 
has focussed on the pathological effects of so-called "toxic" 
oxygen species; however, with the discovery that the nitric oxide 
raducal is an important vasoregulatory agent (Moncada et.al. 
1988) and a neural role for the same has been indicated (Bredt. 
et.al. 1990) and it was recognized that oxygen free radicals may 
also play an important physiological roles indeed, even the 
production of super oxide radicals by normal cells may provide 
an important means of producing and modulating intercellular 
communication. 
Microvascular endotheialialcells not only can be the 
targets of oxident injury, but they are also equipped to produce 
free radicals themselves. Thus the effects of oxygen free radicals 
are particularly relevant to microvasculature function. In 
addition to the general functions of a systemic vascular bed, the 
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cerebral microvasculature performs unique functions related to 
the formation of blood brain barrier (BBB). 
The brain is an ideal site for the destructive action of 
free radicals for several reasons. Brain tissue has an increased 
metabolic rate, high oxygen consumption rate and is rich in 
polyunsaturated lipids, which are particularly vulnerable to free 
radical injury. Certain brain areas contain high levels of catechol 
amines, the oxidation of which yields free radicals (Graham et.al., 
1978) catalase, a major sceavenging enzyme that protects against 
free radicals, is present in only low levels in the brain (Chance 
et. al. 1979) whereas, the content of iron, a transition metal that 
can catalyze the generation of free radicals, is high (Dexter et.al., 
1989). The importance of free radical reactions in radiation damage, 
food preservation has been known for many years. 
The formation of free Radicals 
Electrons within atoms and molecules occupy regions 
of space called orbitals, each of which hold a pair of electrons 
that spin in appointed directions. The main orbital is occupied 
by only one electron, that electron is said to be unparired. A 
radical is defined to be any species that contains one or more 
unpaired electrons. The oxygen molecule qualifies as a radical 
since it has two unpaired electrons in separate orbitals (Halliwell 
and Gutteridge, 1985) (Fig. 5)njhuy76 
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Over 90% of the O2 taken up by aerobic organisms is 
utilized via the mitochondrial electron transport chain, which 
adds four electrons for knowledge of O^ and eventually forms 
two molecules of water, while molecular oxygen can oxidize 
other susceptible molecules by accepting electrons, this process 
is normally quite slow; however, through both spontaneous and 
catalyzed reactions, a variety of other oxygen species may be 
formed that are much more reactive. These include the 
superoxide anion (O^), hydrogen peroxide (H2O2) and the 
hydroxyl radical (OH) (Halliwell and Gutliridge, 1985). when 
one free radical reacts with another fore radical, the resulting 
compound will have an even number of electrons and will no 
longer be a free radical However, when a free radical reacts with 
a non-radical, the resulting compound will also be a free radical. 
However, when a free radical reacts with a non-radical, the 
resulting compound will also be a free radical, thus propagating 
the existence of the radical and potentially producing a more 
highly reactive species, thus resulting in more damage to the 
nearby tissues. 
Lipid Peroxodation (LPO) 
A major mechanism through which the injurious 
hydroxyl radical damages cell components is by the process of 
lipid peroxodation (LPO). Lipid persoxodation is defined as the 
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oxidative deterioration of polyunsaturated lipids (lipids that 
contain three or more carbon-carbon double bonds), following 
an oxidative stress. The term oxidative stress was coined to 
denote "a disturbance in the pro-oxidant-antioxidant balance in 
favour of the former" (Sies, 1985). According to the current 
view, the deterorating effect of LPO originate from the loss 
of membrane structure due to the degradation of phospholipids, 
from the interaction of short living and highly reactive free 
radicals with biomolecules and the formation of non-radical products 
from membrane fatty acids reacting with macromolecules. 
The rate of LPO observed in various tissues depends 
on the presence of antioxidant and pro-oxidant factors of 
endogenous and exogenous origin. 
The pathogenetic role of the LPO process results from 
three causes: 
(1) degradation of the lipid membrane 
(2) interaction of degradation products intra and extracellular 
targets and 
(3) the production of the chain reaction. 
Initiation and Propagation of LPO 
Brain membranes have many polyunsaturated fatty acid 
side chains. Initiation of LPO of brain membranes is due to 
s 
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the attack of any species that has sufficient reactivity, such as 
the hydroxyl radical ( OH) to abstract a hydrogen molecule from 
a polyunsaturated fatty acid. Since the hydrogen atom has only 
one electron, this leaves behing an unpaired electron on the 
lipid side chain. The lipid radical undergoes molecular 
rearrangement and then combines with O^, converting itself into 
a peroxy radical. The peroxy radical then abstracts a hydrogen 
atom from a nearby fatty acid side chain (propagating a chain 
reaction), which converts the peroxy radical into lipid 
hydroperoxide. The end result is an anto catalytic reaction 
resulting in membrane fragmentation and generation of cytotoxic 
aldehydes such as malonedialdelyde figure (6). 
Thiol (SH) groups: 
Mammalian cells have evolved protective mechanisms 
to minimize injurious events that result from toxic chemicals and 
normal oxidative products of cellular metabolism. A major 
endogenous protective system is the glutathione redox cycle 
(Reed, 1986), Glutathione is present in higher concentrations 
as glutathione (GSH) in most mammalian cells (generally in the 
millimolar range), with minor fractions being glutathione 
disulfide (GSSG) mixed disulfides of GSH and other cellular 
thiols and minor amounts of thioethers. Moreover, cysteine, 
present in trivial quantities, also account for the non-protein SH 
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(Kosower and Kosower, 1978). GSH acts both as a nucleophilic 
"scavenger" of numerous compounds and their metabolites via 
enzymatic and chemical mechanisms, converting electrophilic 
centres to tbioether bonds, and as a substrate in the GSH 
peroxidase mediated destruction of hydroperoxides. GSH 
depletion to about 20-30% of total glutathione levels can impair 
the cells defense against the toxic actions of such compounds 
and may lead to cell injury and death (Sies, 1985; Reed, 1986). 
Endogenous oxidative stress is a consequence of oxygen 
in the respiratory chain. It involves the formation of toxic 
oxygen intermediates. About 2-5% of mitrochondrial oxygen 
consumption generates hydrogen peroxide (HjOj) (Chance et al 
1979), which if not reduced, can lead to the formation of the 
very reactive hydroxyl radical and cause the formation of lipid 
hydroperoxides that can damage membranes, nucleic acids and 
proteins and alter their functions. 
Although most glutathione is localized in the cytosolic 
portion, approximately 10% of the total cellular glutathione is 
compartmentalised within mitochondria (Reed, 1990). Because 
mitochondria also contains glutathione peroxidase, glutathione 
reductase and NADPH (generated from NADH via trans 
hydrogenation a complete system for detoxifying hydroperoxides 
is present within these organelles. The mitochondrial pool of 
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GSH is also likely to be involved in maintaining 
intramitochondrial protein thiols in the reduced state. These 
protein thiols are essential for a number of functions of these 
organelles, including selective membrane permeability and Ca^ ^ 
homeostasis, thus, excessive production of HjOj within 
mitochondrial oxidation of protein thiols, and impairment of 
mitochondrial function, providing a clear example of the 
relationship between glutathione status, oxidative stress and 
mitrochondrial damage. 
Nucleic acids 
The discovery of the nucleic acids was the result of 
the work of Friedrich Miescher (1844-1895), the founder of our 
knowledge of the chemistry of the cell nucleus. In 1871 he 
published a paper regarding the isolation of an acidic compound 
"nuclein" from the nuclei of the pus cells, which was readily 
soluble in dilute alkali but insoluble in dilute acid, and contained 
a high proportion of phosphorus (Miescher 1871). A number of 
scientists followed him, but only in 1930, a definite picture of 
two definite types of nucleic acids had emerged. One of them, 
the nucleic acid isolated from yeast, on hydrolysis yielded 
adenine, guanine, cystosine, uracil, phosphoric acid and a sugar 
(pentose), was identified by Levene and Jacobs (1909) as ribose. 
The other nucleic acid obtained from thymus, yielded adenine. 
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guanine, cytosine, thymine, phosphoric acid and a sugar 
(deoxypentose), which was identified as deoxyribose (Levene et 
al 1930). The two nucleic acids, therefore, came to be called 
ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), 
respectively. Initially, an assumption was made that DNAs were 
characteristics of animal tissues and RNAs of plant tissues, but 
later on RNA was found to be present in animal tissue as well 
(Jorpes 1934). 
In the brain, the nucleic acids provided for the storage 
and transmission of genetic informatioin as well as information 
leading to the synthesis of cellular proteins (White et al 1978). 
A knowledge of DNA content helps in understanding 
the tissue components such as average cell densities, dry weight/ 
average cell and total number of cells in each brain area (May 
& Grenell 1959). The only well-authenticated sites at which 
DNA is found in all animal cells including the brain, are the 
nucleus (including nucleolus) and mitochondria (Mahler 1981). 
The DNA content of diploid mammalian cells, including neurons 
and other brain cells, is of the order of 6.5 picograms per cell 
(or about 1 microgram per milligram of wet brain weight). This 
corresponds to a mass of 3.8 x 10'^ daltons for the total 
chromosomal complement of such cells. Thus the maximal 
(haploid) content of genetic information available to these cells 
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is about 800 times that of E. coli, or 100 times that of yeast, 
encoded in 1.5 x 10^ base pairs. The amount of DNA in white 
matter approximately equals that in the cortex, and the regional 
differences in the content of brain DNA are relatively small 
(Logan et al 1952; Elliott & Heller 1957). Cerebellum, however, 
shows exceptionally high amounts of DNA (Grenell 1958, May 
& Grenell 1959). Deoxyribonuclease (DNase) is a highly specific 
phosphodiesterase enzyme responsible for the hydrolytic 
degradation of DNA to mononucleotides and subsequently to 
nucleotides (Schmidt 1955). Neuronal nuclei prepared from 
yound and adult rat brains have been shown to have a higher 
DNase activity than glial nuclei (Stanmbolova 1973). 
The RNA synthesis is expected to be localized at only 
two intracellular sites in all cells of the nervous system: in the 
nucleus, including the nucleolus, and in the mitochondria (Chambon 
1978). Most of the RNA of neurons is localized in the perikaryon, 
and there, as in all cells, the majority forms an integral constituent 
of ribonucleoprotein particles that are themselves aggregated into 
polymeric structures. These structures exist either free in cytosol 
or attached to membranes of endoplasmic reticulum. They are held 
together by messenger RNA (m RNA), and in conjunction with the 
soluble transfer RNA (tRNA) of cytosol, constitute the protein-
synthesiing machinery of the cell. In addition to their peikarya, 
certain neurons contain some RNA in their axons, including the 
•^ • •V > ) . « / 5 5 
presynaptic thickening. The axonal RNA may contribute some 0.5 
mg per gram of wet wright (Koenig 1969). Edstrom (1956) and 
Edstrom and Pigon (1958) have suggested a proportionality between 
RNA content and the surface area of the cell body. It has been 
suggested that, in addition to the established role of nucleic acids 
in the biosynthesis of protein (Campbell 1965), RNA and protein 
synthesis may be involved in the accrual of sensory information in 
the brain, thus indicating a possible approach to elucidation of brain 
functioin on molecular basis (Hyden 1964). 
Amount of RNA in gray matter usually exceeds that in 
white matter (Michailovic et al 1958, Grenell 1958). RNA is highly 
concentrated in the nucleolus and in the Nissl substance of the 
cytoplasm of nerve cells (Landstrom et al., 1941). Ribonoclease 
(RNase), a highly specific phosphodiesterase enzyme, hydrolyzes 
all known RNAs by catalyzing the cleavage of certain strictly 
defined internucleotide bonds (Schmidt 1955). 
1.13.0 Proteins 
Proteins are one of the many important biochemical 
components of the vertebrate brain. They constitute 40% of the 
dry weight and 8% of the wet weight of the fresh brain (Mcllwain 
& Bachelard 1971). Proteins specific to the nervous system are of 
great interest because they underline the developmental 
specialization and differentiation of the CNS cells. Some of the 
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important nervous system specific proteins are S-100 protein, glial 
fibrillar protein, myelin proteins, postsynaptic density proteins, 
receptors for neurotransmitters, enzymes involved in catecholamine 
synthesis, etc. (Mahler 1981). The susceptibility of brain proteins, 
especially those localized in the synaptic region and its membranes, 
to covalent modification may provide a means for altering the 
efficacy of synaptic transmission as a function of neuronal activity. 
As the brain has high rate of metabolic activities, it needs more 
proteins for expected high rate of protein turnover. This view is 
well in agreement with the presence of large amount of cytoplasmic 
ribosomes which provide large number of sites for protein synthesis 
(Mcllwain & Bachelard 1971). 
The changes in the neuronal activity are found to be 
accompanied by perturbations in macromolecules like protein in 
the brain cells. Increased neuronal activity has been reported to 
inhibit the protein synthesis (Hyden and Lange 1972). The specific 
neuronal functions such as conduction of action potentials and 
synaptic transmission are extensively mediated by proteins (Bock 
1978). Proteins in the brain are in a dynamic steady state. Protein 
synthesis probably starts from free amino acids, which are activated 
and transferred to proteins destined for intracellular use are 
synthesized by polysomal arrays in the cytosol, that are unattached 
to membranes. Proteins destined for export from the cell of origina 
s well as those plasma membrane proteins that will become part of 
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its external aspect, are synthesized by polysomes attached to the 
membranes of endoplasmic reticulum. 
Monoamiues 
Monoamines, consisting of catecholamines (CA) and 
serotonin (5-HT) act as important neurotransmitters in the brain. 
Localized in the nerve fibres and nerve terminals, they are 
universally distributed in the CNS, especially in the regions to 
which autonomic or vegetative functions are attributed (Fried 
1966). 
The catecholamines: dopamine, norepinephrine and 
epinephrine, are neurotransmitters, concerned with a number of 
functions related to emotion, attention and visceral regulation. 
Although dopamine (DA) serves as the precursor for 
norepinephrine (NE), and NE may be N-methylated to form 
epinephrine, the three monoamines have separate localizations 
in distinct neuronal pathways (Coyle & Snyder 1981). The cell 
bodies of dopaminergic neurons are located primarily in the mid-
brain, while the noradrenergic neurons cluster in the medulla 
oblongata, pons and mid-brain, in particular locus coeruleus of 
the floor of fourth ventricle. 
Catecholamines are concentrated within storage vesicles 
that are present in high density within the nerve terminals. 
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Ordinarily low concentrations of the catecholamines remain free 
and unprotected in the cytosol. Thus, during biosynthesis 
conversion of tyrosine to L-Dopa and L-Dopa to Dopamine 
occurs in cytosol. Dopamine, then is taken up within the storage 
vesicles. For the noradrenergic neruons, the final hydroxylation 
occurs within the vesicles. The mechanism that concentrates the 
catecholamines within the vesicles is an ATP-dependent process 
linked to a proton pump (Holz 1978). The vesicles play a dual 
role: they maintain a ready supply of catecholamines at the 
terminal, and they mediate the process of their release. When 
an action potential rea/';[p-Oches the nerve terminal, calcium 
(Ca^) channels open, allowing an influx of the cation into the 
terminal; increased intracellular Ca^ ^ promotes the fusion of 
vesicles near the synaptic specialization with the neuronal 
membrane. The vesicles then discharge their soluble contents, 
including NE, AT and DBH, into the extraneuronal space (Coyle 
& Snyder 1981). Inspite of marked fluctuations in the activity 
of catecholaminergic neurons the levels of catecholamines within 
the nerve terminals remain relatively constant. Through such 
mechanisms an end-product inhibition, transient activation, and 
enzyme inductioin, the neuron can accommodate to alterations 
in utilization of catecholamine neurotransmitters (Joh et al 
1978). The action of catecholamines released at the synapsis is 
terminated primarily by reuptake into the nerve terminals that 
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release the neurotrasmitters. Catecholamines that have not been 
removed from the synaptic cleft by the transport process diffuse 
into intracellular space, where they are catabolized by the 
enzyme, monoamine oxidase (MAO) and catechcol-o-methyl 
transferase (COMT) (Fig. 7). The catecholamine reuptake 
process was discovered by Axelrod (1971). 
Serotonin or 5-hydroxytryptamine (5-HT) is widely 
distributed in the body of coelenterates, arthopods, molluscs, 
tunicates and vertebrates. Like acetylcholine and catecholamines, 
serotonin acts on many body organs either directly or by a 
neuronal reflex. Its actions on the cardiovascular, respiratory and 
gastrointestinal systems are especially prominent. 
The CNS contains a relatively small amount (about one 
percent) of the serotonin in the body. The distribution of 
serotonin in the brain is uneven. The brain-stem has the highest 
concentration, the cerebral cortex has moderate while cerebellum 
has a low concentration (Saavedra et al 1973). A family of 
neurons in the pons and mesencephalon is the primary source 
of serotonin in the brain (Michael 1981). These neurons are 
found in or near the midline, or in the raphe nuclei, in clusters. 
Sertonin is stored in synaptic vesicles in nerve endings. It 
appears to be synthesized outside the vesicles and then taken 
into them (Job et al; 1975). Finally, it is released by an 
61 
excitotoxic process. The most important enzyme in catabolising 
serotonin is monoamine oxidase A, which oxidizes the amino group 
of serotonin to form an aldehyde, 5-hydroxyindoleacetaldehyde, 
which usually oxidizes to yield 5-hydroxyindoleacetic acid (5HIAA) 
(Fig. 8). Enz>Tnatic degradation by MAO helps to limit the 
biological actions of 5-HT (Serotonin), so does reuptake into nerve 
terminals. Both serotonergic and other monoaminergic terminals can 
take up 5-HT. Occupation of presynaptic 5-HT "autoreceptors" on 
serotonin-containing neurons reduces the neuron's rate of 
spontaneous firing. This provides a mechanism for feedback 
inhibition of neuronal activity that is coupled to the release of 
transmitter. 
5-HT has been implicated in numerous central 
processes, including regulation of the anterior pituitary, sleep, 
perception of pain, thermoregulation, control of blood pressure, 
appetitive behaviour, drinking, respiration, heart-rate and 
rhythmic behaviour. 
Proposed mechanisms of Excitotoxic injury 
The suggested mechanisms underlying EAA 
neurotoxicity can be divided into two distinct component 
processes based on w vitro studies. (Fig. 9) (Rothman & Olney 
1987; Choi, 1988). The first involves depolarization of neuronal 
membranes, Na" influx followed by secondary passive CI" and 
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HjO influx, and subsequent neuronal swelling. The second phase 
is characterized by excessive calcium influx, primarily via 
NMDA receptor/channel activation, activation of second 
messenger systems, mobilization of internal Ca^^ stores, 
activation of lipases and proteases, generation of fatty acids and 
free radicals, mitochondrial dysfunction and depletion of energy 
stores. These cellular derangements may lead to the destruction 
of neuronal cytoskeletal and membrane components and 
ultimately neuronal death. In fact this scenario appears to be 
a central pathway leading to neuronal injury resulting in cell 
death. 
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IMATERIALS AND JVIETHODS 
1. (i) Animals and treatment 
Wistar albino rats of Animal house of J.N. Medical 
College breeding colony were used in all the experiments 
described in this presentation. Normal female rats of proven 
fertility were mated with normal males in the ratio of 3:1. 
Every morning the vaginal smears test was done and sperm-
positive rats were separated and the day was marked as zeio 
day of pregnancy. Pregnant females were divided into two 
groups: (a) control and (b) Glu-exposed. These rats were housed 
individually in plastic cages under standard laboratory 
conditions (light/dark schedule; 12/12 hour: 21 ± 2 °C and fed 
ad libitum rat pellet diet from Hindustan Lever Laboratory 
Animal Feed, Calcutta, India. Experimental group was exposed 
to the varying doses of Monosodium Glutamate 50 mg/kg body 
weight from zero day of pregnancy throughout gestational and 
lactational periods. In certain experiments where a continuation 
of exposure was required, weaned pups were given Glu-drinking 
water. A complete record of dams/pups was maintained 
throughout the experiment. At parturition, the litter size was 
adjusted to eight pups, randomly among the nursing mothers. At 
21 days of age, pups were separated from their mothers and were 
allowed to chew laboratory animal food ad libitum. The animals 
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were sacrificed at the desired time intervals by cervical 
decapitatioin and processed for biochemical analysis. 
(ii) Chemicals and reagents 
All biochemicals and standards used for the study were 
obtained from Sigma Chemical Co. (St. Louis, MO), namely, 
Disodium ATP, Ouabain, 5' AMP (disodium salt), 2;3'-cyclic 
Adnosine monophosphate (disodium salt). Alkaline phosphatase. 
Acetyl thiocholineiodide, Phenolphthalein mono glucuronide, 
sodium succinate, NADH, NADPH, Glutathione oxidized 
(GSSG), Glutathione reduced (GSH), DNA, RNA. Dopamine, 
DL-norepinephrine -HCL, 5-Hydroxytryptamine, Cholesterol, 
Triolein, Galactocerebroside, Galactocerebrosulphatide, 
Phoshatidylethanolamine (PE), Phosphatidylcholine (PC), 
Phosphatidylserine (PS), phosphatidylinositol (PI), 
Sphingomyelin (SG) and N-acetyl neuraminic acid. Other 
reagents and solvents used were of Analytical grade and of 
highest purity, which were obtained from Sisco Research 
laboratories. Spectrochem and BDH, Bombay, India, Radioactive 
['H]-thymidine was obtained from Bhabha Atomic Research 
Centre, Bombay, India. 
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2. Biochemical Studies ^^  -^ / TO y ^^  
Preparation of homogenate 
Bra ins were taken out immedia te ly after 
decapitation, washed 2-3 times with chilled normal saline 
( 0 . 9 % w/v. NaCl) to remove exces s of blood and 
membranes, in ice cold conditions. A 10% (w/v) homogenate 
was prepared in 0.32 M sucrose with the help of potter 
elvehjem homogenize! in an ice bath. A portion of this 
homogenate was kept for enzyme assays and rest was used 
for subcellular factionation. 
Subcellular fractionation of brain tissue 
Homogenate was centrifuged at 0.4 °C, at the speed 
of 700 g for 10 minutes in refrigerated centrifuge to separate 
nuclear fraction, supernatant thus obtained was recentrifuged 
at 15000 g for 30 minutes. The mitochondrial pellet obtained 
was washed 2-3 times with chilled 0.32 M sucrose and again 
cent r i fuged at 15.000 g for 30 minu te s . Pellet was 
resuspended in the original volume of the homogenate to 
make 10% mitochondiral preparation, used for the assay of 
enzymes. 
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Enzymatic Analysis 
2.1.1 Na% K^ - Adenosine triphosphatase (Na% K^-ATPase) 
(ATP posphohydrolase, E.C. 3.6.1.4) 
Enzyme activity was measured in brain homogenate 
according to the method of Abdel latif et al., (1970). Assay 
system for total Na", K.' and Mg^"-ATPase consisted of 1.0 ml 
of 40 mM tris-HCl buffer, pH 7.4 containing 6 mM MgCl,, 20 
mM KCl, 150 mM NaCl, 0.1 ml of enzyme (10 mg tissue) and 
0.1 ml of 40 mM ATP in a total volume of 1.2 ml. the mixture 
was incubated at 37°C for 30 minutes.. Assay system for Mg^"-
ATPase was the same as described above except that it contained 
0.7 iimoles of Ouabain in total 1.2 ml of reaction mixture. After 
incubation reaction was stopped by adding 1.0 ml of 10% TCA. 
kept in cold for 15 min and centriguged at 2,000 RPM for 10 
min. 0.5 ml supernatant was taken for inorganic phosphorus 
estimation. 
Inorganic Phosphorus (Pi) estimation 
Solvent extraction procedure was used for the 
estimation of inorganic phosphorus according to the method 
described by Berenblum and Chain (1938) as modified by Martin 
and Dotty (1974). Colour was developed by mixing 0.5 ml 
supernatant for the ATPase assay system, 2.0 ml of isobutanol: 
benzene (1:1) and 2.0 ml of 1.5% (w/v) ammonium molybdate 
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in 0.5 N H^SO^. The contents were mixed vigorously and 
centrifuged at 2.000 RPM for 10 min. Upper solvent phase was 
removed carefully into the cuvette and O.D. was read at 410 
nm in LKB spectrophotometer. Activity of Na", K^ and MgH-
ATPase and Mg^^-ATPase was measured in the presence of 
Ouabain. Enzyme activity was expressed as ^imoles of Pi 
liberated/min/mg protein. 
2.U.5'Nucleotidase (5'N):(5'-Ribonucleotide phosphohydrolase, E.C. 3.13.5) 
Enzyme was assayed by measuring the Pi liberated from 
5'-adenosine monophosphate (5'-AMP) by the method of Arch 
and Newsholme (1978). Incubatioin mixture consisted of 0.2 ml 
of 100 mM Tris-HCl buffer, pH 7.5 containing 12.5 mM 5'-AMP 
and 5 mM MgCl, and 0.05 ml of enzyme (10% homogenate) in 
a total volume of 0.25 ml of assay system. The reaction mixture 
was incubated at 37°C for 20 minutes. Reaction was stopped by 
adding 0.25 ml of 2.5 M H.SO^, centrifuged at 2,000 RPM for 
10 min and supernatant was used for the estimation of Pi as 
described earlier. Enzyme activity was expressed as ^imoles of 
Pi liberated/min/mg protein 
2.1 J 2'J'-CycMc nucIeotide-3' phosphohydrolase (CNPase): (E.C. 3.1.4.1) 
Assay was done according to the method of Prohaska 
et al. (1973) using 2',3' cyclic adenosine monophosphate (2',3'-
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cAMP) as substrate by coupled system with excess of alkaline 
phosphatase and subsequent determination of liberated Pi. Before 
enzyme assay, homogenate was solubilized by mixing 0.1 ml of 
0.2oM Tris-HCl buffer pH 7.5, 0.2 ml of 10% homogenate and 
0.2 ml of 1% (w/v) sodium deoxycholate, kept at 0.4 °C for 10 
min and diluted to get 100 |ig protein/ml. 
Assay mixture consisted of 0.2 ml detergent treated 
protein (20 |ig), 0.5 ml of 15mM, 2;3'cAMP (Prepared in 50 mM 
Tris-maleate buffer, (pH 6.2) and 0.3 ml of 50 mM tris-maleate 
buffer, (pH 6.2) in a total volume of 1.0 ml. Reaction mixture 
was incubated at 30°C for 10 min. Reaction was terminated by 
placing the tubes in boiling water bath for 30 seconds. Tubes 
were again kept at 30 °c for 20 min in water bath with 
subsequent addition of 0.4 ml of 0.3 M Tris HCl buffer, pH 
9.0, containing 21 mM MgClj and 0.1 ml (60 |ig) of Alkaline 
phosphatase. After incubation, reaction was stopped by adding 
1.0 ml of 3% (w/v) TCA, centrifuged at 2,000 RPM for 10 
min. 1.0 ml supernatant was taken out for Pi estimation as 
described earlier. Enzyme activity was expressed as umoles of 
Pi liberated/min/mg protein. 
2.1.4 Acetylcholinesterase (AChE): (Acetylcholine hydrolase, E.C 3.1.1.7) 
AChE was assayed according to the method described 
by Ellman et al., (1961) using acetylthiocholineiodide as 
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substrate. Incubation mixture in a total volume of 3.13 ml 
consisted of 3.0 ml of 100 mM phosphate buffer pH 8.0,0.02 
ml of 75 mM acetylthiocholine iodide 0.10 ml of lOmM DTNB 
containing 17.85 mM NaHCOj in 100 mM phosphate buffer, pH 
7.0. Contents were mixed and preincubated at 25°C for 5.0 min. 
Reaction was started by adding 0.01 ml of enzyme (10% 
homogenate). Activity was monitored for 5.0 minutes at 30 sees, 
interval at a wavelength of 410 nm. The enzyme activity was 
exprressed as |j.moles of acetylthiocholineiodide hydrolyzed/min/ 
mg protein. 
2.1.5 ^-Gluciironidase: (Glucuronide ghicuronohydrolase, £. C. 32.131) 
Enzyme was assayed in brain homogenate by the 
method of Fischaman et al. (1967). Incubation mixture in a 
total volume of 1.0 ml consisted of 0.3 ml of 0.1 M acetate 
buffer, pH 4.5, 0.1 ml of 0.01 M phenolphthalein 
monoglucoronide, 0.5 ml of 10% homogenate and 0.1 ml of 
distilled water. The contents were mixed and incubated at 37°C 
for 1 hour. Reaction was terminated by adding. 1.0 ml of 10% 
TCA and centrifuged at 2,000 RPM for 10 min Supernatant was 
used for the colour development. 
Composition of alkaline glycine reagent 
It consisted of 16.30 g glycine, 1265 g NaCl and 10 90 
ml of 50% NaOH. Volume made upto 100 ml, pH 10.20. 
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Colour Development 
1 ml supernatant was mixed with 2.0 ml of alkaline 
glycine reagent and O.D. read at 540 nm. Enzyme activity was 
expressed as nmoles of phenolphathalein liberated/hour/mg 
protein. 
Assay of mitochondrial enzymes 
2.1.6 Succinate dehydrogenase (SDH): (Succinate (acceptor) 
Oxidoreductase, E.C. 1.3.99.1) 
The enzyme activity was determined according to the 
method of Slater and Bonner (1952). The incubation mixture in 
a total volume of 2.0 ml consisted of 0.4 ml of 0.5 M phosphate 
buffer, pH 7.2, 0.4 ml of 0.1 M K3Fe(CN), 0.2 ml of 0.1 M 
KCN, 0.2 ml 10% (w/v) mitochondrial suspension and 0.7 ml 
of distilled water. Preincubated at 37°C for 3.0 min and reaction 
started by adding 0.1 ml of 0.1 M sodium succinate. Incubation 
was carried out at 37''C for 15 min. The reaction was terminated 
by adding 4.0 ml of 5% TCA. Tubes were kept in cold for 15 
min and then centrifuged at 2.000 RPM for 10 min. The O.D. 
of supernatant was read at 400 nm. The enzyme activity was 
expressed as umoles of K3Fe)CN)^ reduced/min/mg protein using 
9.09 x 10' cm^/mole as a molar extinction coefficient of K,Fe 
(CN),. 
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2.1.7 Malate dehydrogenase (MDH): (L-malate NAD-oxidoreductase, 
E.C. 1.1.1.3) 
Enzyme was assayed according to the method of Ochoa 
(1955). Assay mixture in a total volume of 3.0 ml consisted of 
0.3 ml of 0.25 M Tris HCl buffer pH 7.4. 0.1 ml of 0.0015 
M NADH. 0.1 ml of 0.0076 M oxaloacetate, 2.48 ml of distilled 
water and 0.02 ml of 10% (w/v) mitochondrial suspension. 
Contents were mixded and the reaction was monitored at 30 
seconds interval, for 3 min at 340 nm. The activity was 
expressed as nmoles of NADH oxidized/min/mg. protein using 
6.22 x 10^  cm /^ mole as molar extinction coefficient of NADH. 
2.1.8 Diaphorase: (reduced NAD lipoaimde OHdoreductase, E.C. 1.6.43) 
The enzyme activity was determined according to the 
method of Mahler (1955). The incubation mixture in a total 
volume of 3.0 ml consisted of 0.3 ml of 0.2 M Tris-HCl buffer, 
pH 7.4. 0.1 ml of 0.0012 M 2.6-dichlorophenol indophenol, 2.4 
ml distilled water and 0.1 ml of 1.0% (w/v) mitochondrial 
suspension. Reaction was started by adding 0.1 ml of 0.06 M 
NADH. The contents were mixed and change in O.D. was 
recorded at 30 second intervals for 3.0 min at 600 nm. Enzyme 
activity was expressed as ^moles of 2,6-dichlorophenol 
indophenol reduced/min/mg protein using 21 x 10^ cmVmole as 
molar extinction coefficient of 2.6-dichlorophenol indophenol. 
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2.1.9 Thymidine kinase (TK): (ATP; thymidine 5'-phosphotransferase, 
E.C. 2.7.1.21) 
Enzyme preparation 
A 10% w/v homogenate of brain tissue was prepared 
in 0.2 M Tris-HCl buffer, pH 7.4 containing 0.25 M sucrose and 
4 mM MgClj. Centrifuged at 100,000 g for 60 minutes (0-4 °C) 
in an ultracentrifuge. Supernatant was collected for the assay 
of TK. 
Enzyme was assayed according to the method of Prasad 
el al. (1974). Incubation mixture in a total volume of 0.25 ml 
consisted of 0.1 ml of 0.1 M tris-HCl buffer, pH 8.0,0.01 ml 
of 0.3 M MgCl2, 0.01 ml of 0.3 M phosphoglyceric acid, 0.01 
ml of 0.3 M ATP, 11.3 ^1 of 44.25 \xM [^HJ-thymidine (11.3 
nci), (final concentration 500 pmoles of [^H]-thymidine/assay 
system). 0.01 ml distilled water and 0.10 ml of supernatant. 
Incubated at 37°C for 15 min. Reaction was stopped by 
immersing the tubes in boiling water bath for 3 min. and cooled 
immediately in ice water. Centrifuged at 5,000 RPM for 10 min. 
Discs of DEAE celulose paper (Whatman DE-81) were spotted 
with 50 |il of reaction mixture and then air dried. The discs 
were washed with 10 ml portions of the following: 3 times with 
0.005 M NH^HC03, twice with acetone and once with ether using 
Millipore filteration assembly. The discs were dried and 
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transferred to scintillation vials containing 5.0 ml of scintillation 
fluid. 500 pmoles [^H]-thymidine as a standard was spotted (in 
triplicate) on separate discs and directly transferred to the 
scintillation vials. Counting was done in a Rack Beta 
Scintillation counter (LKB). The enzyme activity was expressed 
as nmoles of thymidine monophosphate formed/hour/mg protein. 
Composition of Scintillation cocktail 
4.9 g of diphenyl oxazole (PPO) and 0.1 g of 1.4-
bis (phenyloxazole2-yl) benzene was mixed in a total volume 
of 1000 ml toluene. 
2.2 Assay of Antioxidant enzymes 
Tissue processing 
Ten rats from each control and Glu-exposed group at 
day 1 and 7 of age and five rats from both the groups at 14 
and 21 days were sacrificed by decapitation. Brains were taken 
out, washed in normal saline, soaked on filter paper and 
weighed. A 20% w/v homogenate was prepared in chilled normal 
saline (0.9% w/v NaCl). subcellular fractionation was done as 
described earlier. 
2.2.1 Glutathione Reductase (GR): (NADPH: Oxidized glutathione 
oxidoreductase, E.C. 1.6.4.2) giuiainione 
GR was assayed according to the method of Beulter 
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(1969) in post mitochondrial supernatant (PMS). Assay mixture 
in a total volume of 3.0 ml consisted of 2.5 ml of 0.067 M 
phosphate buffer, pH 6.6, 0.2 ml of 7.5 mM GSSG. 0.2 ml of 
enzyme and 0.1 ml of 6 mM NADPH.. Enzyme activity was 
monitored for 3.0 min. by recording change in O.D./30 seconds 
at 340 nm. Enzyme activity was expressed as nmoles of NADPH 
oxidized/min/mg protein using 6.22 x 10^ cmVmole as molar 
extinction coefficient of NADPH. 
2.2.2 Glutathione peroxidase (GPx): l]NAD(P) H: Oxidised 
glutathione oxidoreductase, E.G. 1.11.1.9]. 
GPx was assayed according to the procedure of Rotruck 
et al. (1973) in PMS fraction. Incubation mixture in a total 
volume of 1.0 ml consisted of 0.2 ml of 0.2 M tris-HCl buffer, 
pH 7.4, 0.2 ml of 2 mM GSH, 0.1 ml of 10 mM sodiumazide, 
0.1ml of distilled water, 0.3 ml of enzyme and 0.1 ml of ImM 
HjOj. The assay mixture was incubated at 37 °C for 15 min 
and the reaction was terminated by adding 0.5 ml of 10% TCA. 
Tubes were kept for 10 min at 0. 4°C and centrifuged at 4.000 
RPM for 10 minutes. 
Colour development 
Leftover GSH was measured in 0.5 ml supernatant 
by adding 2.0 ml of 0.1 M phosphate buffer, pH 7.4 and 0.5 
ml of 0.04% DTNB in 0.3 mM Na^HPO, Mixed well and O.D. 
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was recorded immediately at 420 nm. Enzyme activity was 
expressed as nmoles of GSH oxidized/min/mg protein. 
2.2.3 Superoxide dismutase (SOD): (Superoxide: Superoxide 
oxidoreductase, E.C. 1.15.1.1). 
SOD was assayed by the method of Minami and 
Yoshikawa (1979) in PMS fraction of brain homogenate. The 
assay system in a total volume of 3.01 ml consisted of 0.3 ml 
of 1.0 mM tris-cacodylate buffer containing 10 mM Diethylene 
triamine penta acetic acid (DTPA) (chelating agent), pH 8.2, 0.3 
ml of Nitroblue tetrazolium, 0.3 ml of 0.01% Triton X-100, 0.5 
ml of enzyme, 0.4 ml of distilled water and 0.01 ml of 60 mM 
pyrogallol. The contents were mixed carefully and reaction was 
monitored for 5 min by recording change in O.D./30 seconds 
at 540 nm. Enzyme activity expressed as units/min/mg protein. 
One unit is defined as the amount of enzyme required for the 
50% inhibition of pyrogallol auto-oxidation. 
2.2.4. Catalase (Hydrogen peroxide: hydrogen peroxide oxidoreductase, 
E.C. 1.11.1.6) 
Activity of catalase was assayed in the homogenate 
treated with Triton-X 100 (final concentration 0.01% v/v/) by 
the method of Aebi (1983). The assay system in a final volume 
of 3.061 ml consisted of 3 ml of 50 mM phosphate buffer. pH 
7.2, 0.039 ml of 0.97 M Up^ (final cone. 12.36 mmole/1 assay 
system) and 0.025 ml of enzyme. The contents were mixed 
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carefully and change in O.D. was recorded after every 10 second 
interval for 1.5 min at 240 nm. Enzyme activity was expressed 
as n moles of Hp^ oxidized/min/mg protein, using 40.0 cm^/ 
limole as the extinction coefficient of H2O2 
Measurement of antioxidant substances 
2.2.5 Glutathione content (GSH) 
Brain GSH contents were measured by the method of 
Ellman (1959) as modified by Jollow et al. (1974) 
1.0 ml homogenate was mixed with 4% w/v 
sulphosalicyclic acid and kept for one hour in cold for complete 
precipitation of proteins, centrifuged at 4,000 RPM for 15 
minutes. 
For colour development 0.2 ml SSA supernatant was 
mixed with 4.0 ml of 0.1 M phosphate buffer, pH 7.4 and 0.2 
ml of 0.01 M DTNB (prepared in phosphate buffer). The 
reaction mixture was incubated at room temperature for 30 
minutes and O.D. was read at 412 nm against reagent blank, GSH 
contents were expressed as umoles of GSH/g wet tissue. 
2.2.6 Total sulphydryl groups (TSH) 
Levels of TSH in brain tissue was quantitated by the 
method of Sedlack and Lindsay (1968). For colour development 
89 
1.0 ml of sulphosalicylic acid (SSA) supernatant was mixed with 
2.0 ml of 0.2 M Tris-HCl buffer pH. 8.2, 0.2 ml of 0.01 M DTNB 
and 4.0 ml of cold methanol with a final volume of 7.2 ml. 
The contents were mixed and incubated at room temperature for 
30 min and O.D. was read at 412 nm against reagent blank. 
TSH was expressed as |imoles/g wet tissue using GSH as 
standard. 
2.3 Protein Estimation 
Protein was estimated in brain homogenate and 
subcellular fractions by the method of Lowry et al. (1951) using 
BSA as standard. TCA-precipiated proteins were dissolved in 1 
N-NaOH. Colour was developed by mixing 0.05 ml of protein 
aliquot, 0.45 ml distilled water and 5.0 ml of alkaline copper 
reagent and preincubated for 10 min at room temperature. Finally 
0.5 ml of 1 N Folin-Ciocalteu's reagent was added and again 
kept for 30 min at room temperature. O.D. was read at 660 
nm. Protein contents wer expressed as mg protien/ml. 
2.4 Lipid Peroxidation 
Formation of lipid peroxides was determined by the 
thiobarbituric acid (TBA) test according to the method of 
Ohkawa et al. (1980). 
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5.0 ml of brain homogenates (10% w/v) prepared in 
0.15 M KCl were taken in 25 ml Erlenmeyer flasks and incubated 
at 37 °C with a speed of 200 oscillation/min in a metabolic 
shaker (Scintronic) over a period of 1 hour for maximal lipid 
peroxidation. One ml aliquot was drawn from each flask and 
mixed with 1.0 ml of 35% TCA. Kept in cold for 2 hours and 
centrifuged at 3,000 RPM for 15 minutes. 1.0 ml supernatant 
was taken for colour development by adding 1.0 ml of 0.67% 
(w/v) aqueous TBA and 1.0 ml of distilled water. After mixing 
the contents, tubes were kept in boiling water bath for 15 
minutes and cooled under tap water. Colour intensity of 
thiobarbituric acid reactive substances (TBRS) was read at 530 
nm against reagent blank. Calculations were made by using 1.56 
X 10' as the molar extinction coefficient of MDA. Lipid 
peroxidation was expressed as nmoles of MDA formed/hour/ 
g wet tissue. 
3. 0 Nucleic Acids: Extraction of DNA and RNA 
Extraction procedure has been shown in attached flow-
chart (3.0). 
Preparation of reagents for DNA and RNA estimations 
1. Diphenylamine reagent 
1 gm of purified diphenylamine was dissolved in 100 
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ml of glacial acetic acid and 2.75 ml of concentrated H^SO^ 
2. Orcinol reagent 
1 gm of purfied Orcinol was dissovled in 100 ml of 
concentrated HCl containing 0.5 g of FeClj. 
3.1 DNA estimation 
1.0 ml of DNA extract was mixed with 2.0 ml of 
diphenylamine reagent and heated for 10 minutes in boiling 
water bath. The intensity of blue colour was read at 600 nm. 
DNA contents were expressed as mg/g wet tissue. 
3.2 RNA estimation 
1.0 ml of RNA extract was mixed with 1.5 ml of 
Orcinol reagent and was heated for 20 minutes in boiling water 
bath. The intensity of the green colour was read at 660 n. RNA 
contents were expressed as mg/g wet tissue. 
3.3 DNA sysnthesis 
Five rats from both control and Glu-treated groups 
at postnatal age of 7,14 and 21 days were injected i.p. to a 
single dose of 0.5 uci [^H]-thymidine/g body weight (specific 
activity, 22,600 mci/m mole) and were sacrificed by decapitation 
after 2 hours. Brains were removed and placed on ice rinsed 
soaked on ash-free filter paper and 10% (w/v) homogenate was 
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Sediment 
Se dim 
3.0 Nucleic acids: Extraction of DNA and RNA 
2.0 ml f 10% w/v homogenate in (09% w/v)NaCl 
ent 
Washed with 2.5 ml of 10% cold TCA 
Centrifuged at 10,000 RPM for 10 minutes 
Supernatant (discarded) 
Added 5.0 ml of 95% absolute 
alcohol Centrifuged at 10.000 
RPM for 10 minutes 
Sediment Supernatant (discarded) 
Suspended in 4.0 ml of IN-KOH, 
Incubated for 20 hours at 37 °C 
Added 2.5 ml of 10% cold TCA centrifuged at 
10,000 RPM for minutes 
Suprmatant 
(discarded) 
2.0 ml taken for 
RNA estimation 
Sediment 
2.0 ml processed for 
DNA estunation 
Added 0.4 ml of 2 N-HCl and 2.0 ml of 5% 
TCA Centrifuged at 10,000 RPM 
for 10 minutes 
Sediment Supernatant (discarded) 
(i) Suspended in 1.3 ml water and 1.3 ml of 10% TCA 
(ii) Heated at 90°C for 15.0 min. with occasional stirring 
(iii) Centrifuged at 10,000 RPM for 10 minutes 
Supernatanr (discarded) 
Washed with 1.0 ml of 5% TCA 
Sediment(discarded) Supermatant 
Supermatants I and II pooled and used for DNA estimation. 
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prepared in physiological saline. An aliquot was kept for protein 
estimation by the method of Lowry et al. (1951) and the rest 
of the homogenate was processed for the isolation and estimation 
of nucleic acids according to the method of Schneider (1957). 
After removal of lipids from acid insoluble portion, the pellet 
was suspended in the required volume of 1 N-KOH and 
incubated for 20 hours at 37 °C A 0.5 ml aliquot was taken 
for counting after neutral iz ing with dilute HCl. 10 ml 
scintillation cocktail was added to the suitable aliquot in 
scintillation vials and counting was done in LKB Liquid 
Scintillation Counter. 
Composition of Scintillation Cocktail 
2.5 Diphenyloxazole 
1.4-bis (5-phenyl oxazoyl) benzene 
Naphthalene 
Ethylene glycol 
Methanol 
8.00 gm 
0.40 gm 
120.00 gm 
40.00 ml 
200.00 ml 
Dissolved in approximatley 1000 ml of dioxane and 
made the volume upto 2000 ml. 
4.0 Extraction and Estimation of Biogenic Amines 
The organic solvent extraction procedure of Jacobwitz 
and Richardson (1978) was followed for estimation of biogenic 
amines. The different parts of central nervous system were 
seperated as described in the extraction procedure given below. 
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Extraction procedure 
Weighed tissue sample (0.5 g) 
(frozen) 
+ 5.0 ml chil ed butanol and 
0.4 ml of .01 N HCl 
Homogenized in a potter Elevhjem homogenizer under cold 
conditions for about 2.3 minutes unit tissue is uniformly 
distributed throughout the butanol. 
Contents were transferred into a 15.0 ml tubes and then 
centrifuged at 3.000 RPM for 10 minutes in cold. Supernatant 
was used for further processing. 
For 5 Ht 
Pipetted 2.0 ml butanol 
into centrifuge tube 
containing 5.0 ml chilled 
and 0.5 ml of 0.1 N HCl. 
Tubes were kept in ice water 
Vortexed for 1 min. 
Centrifuged at 3,000 RPM 
for 10 min in cold centrifuge 
For NE and DA 
pipetted 2.0 ml butanol 
supernatant into 
centrifuge tube containing 
1.5 ml of 0.1 n heptane 
phosphate buffer, pH 6.5. 
Tubes were kept in ice water 
Vortexed for 1 min. 
Centrifuged at 3,000 RPM 
for 10 min in cold centrifuge 
Aspirated the top organic layer including any tissue disc, leaving 
the clear aqueous phase for the estiamtion of NE, DA and 5 
-HT fluorimetrically. Schimadzu RF -5000 spectrofluorometer 
was used for the present work. 
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Reagents 
1. Phosphate buffer 0.1 M, pH 6.5 
2. EDTA: Prepared by dissolving 4 g of disodium ethylene 
diamine tetraacetic acid (EDTA) in 95 ml of distilled water 
and pH adjusted between 6.0 and 6.5 Volume made upto 
100 ml. 
3. Iodine solution: Dissolved 4.8 g of Potassium iodide (KI) 
and 0.2 g iodine in 100 ml of distilled water. 
4. Alkaline sulphite: Prepared fresh daily by dissolving 2.5 
g of sodium sulphite (Na^SO,) in 100 ml of 4 N-NaOH. 
5. Ortho-phthaldialdehyde (OPT): Prepared fresh daily by 
dissolving 50 mg OPT in 100 ml of absolute methanol. 
6. 0.01 NHCl: 0.43 ml of concentrated HCl (11.6 N) made 
upto 500 ml with distilled water. 
7. 5N acetic acid: 147 ml of acetic acid (17 N) made upto 
500 ml with distilled water. 
4.1 Estimation of NE and DA 
1.0 ml aqueous phase and standards of NE and DA at 
varying concentrations were taken into seperate tubes for the 
development of fluorophores. Added 0.25 ml fo EDTA and 
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vortexed. Exactly after 2 min interval added 0.2 ml of iodine 
and again vortexed. Added 0.25 ml of alkaline sodium sulphite 
and mixed properly. Finally, 0.3 ml of 5 N-acetic acid was 
added and vortexed gently. In the blank tubes, EDTA is not 
added and alkaline sodium sulphite is added before the iodine. 
Tubes were kept in boiling water bath for exactly 5 minutes, 
placed in ice water for 1 min. and read NE fluorescence 
immediately at excitation 385 nm/emission 485 nm.DA 
fluorescence was read at least 20 min later at excitation 320/ 
emissioin 385. NE and DA levels were expressed as ug/g wet 
tissue in different brain regions. 
4.2 Es t imat ion of 5-hydroxytryptamine 
0.6 ml of HCl extract and suitable amount of standard was 
pipetted in different tubes. Added 0.4 ml of OPT solution. 3.0 
ml of concentrated HCl was added immediately and vortexed. 
Reagent blank was prepared by adding 0.75 ml of 0.01 N HCl 
to 5.0 ml butanol. HCl extract was processed as discused above. 
All the tubes were kept in boiling water bath, for 10 minutes. 
Cooled under tap water and read fluorescence at excitation 360/ 
emission 470. 5-HT levels were expressed as ug/g wet tissue in 
different brain regions. 
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4.3 Behavioural Study 
Batches of five animals selected randomly from control, 
and Glu-exposed and Glu-withdrawal group were subjected to 
monitor the Spontaneous locomotor activity (SLA). Rats were 
placed individually in a photoactometer in which the frequency 
with which the animals interrupt the light beam was measured 
as described by Kuhn and Mannen (1961). Activity counts of 
individual rat was recorded for a period of 5 minutes for three 
consequently days, after one minute acclimatization. 
5.0 Extraction and Estimation of Lipids 
Lipid extraction 
Five brains each from control and Glu-treated group were 
taken for lipid estimations at 15.21,30 and 45 days of postnatal 
age. Weighed tissue was homogenized in a Potter Elvehjem 
homogenizer with 2.0 ml volumes of chloroform: methanol (2:1) 
according to the method of Folch et al. (1957). Homogenate 
was filtered through the ash free (Whatman No. 1) filter paper 
previously wetted with the solvent. Filter papers was washed 2-
3 times with small volumes of solvent to ensure complete lipid 
extraction. All the washings were pooled togather. The crude 
lipid extract was mixed thoroughly with 2.0 ml Of 0.88% KCl, 
kept for about 2 hours and centrifuged at 4,000 RPM for 10 
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minutes. Both upper and lower solvent phases were separated 
carefully in glass stoppered vials. Lower phase was washed 2-
3 times with small volumes of pure solvent upper phase (C:M 
0.8% CKl), mixed gently and centrifuged. All the upper phases 
were removed to ensure that the lower phase is completely free 
from polar lipids (mainly gangliosides), and were pooled 
together. Total volume of the upper and lower phases were 
recorded and the samples were stored at -20 °C until further 
analysis. 
5.1 Estimation of Total lipids 
Total lipids were estimated gravimetrically. 2.0 ml of lipid 
extract was added to the preweighed vials after achieving 
constant weight (Wj). Solvent was evaporated and the vials were 
kept in a dessicator. Weight of the vials were recorded 2-3 times 
until constant weight was achieved (W^). Lipid weight was 
recorded by substracting initial weight from the final weight 
(Wj-W,). total lipids were expressed as mg/g wet tissue. 
5.2 Cholesterol estimation 
Cholesterol estimation was done according to the 
method of Zlatkis et al. (1953). 
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Reagents 
1. Stock FeCl3 reagent: 1 gm of anhydrous FeClj dissolved in 
10 ml of aldehyde free glacial acetic acid. 
2. Working FeClj reagent: It was prepared fresh by mixing 1 
ml of stock FeClj reagent with 100 ml of concentrated 
3. Standard cholesterol (1 mg/ml) : 10 mg of purified 
cholesterol was dissolved in 10 ml of chloroform in a 
volumetric flask. 
Procedure 
Varying concentrations of standard cholesterol (10-100 ug) 
and suitable amounts of lower phase extracts were taken 
separately. Samples were dried free of solvent. 3.0 ml of 
aldehyde free glacial acetic acid was added to each tube and 
mixed on a Rota-mixer (Remi). 2.0 ml of working FeClg reagent 
was added to each tube and mixed properly. Blank tubes were 
prepared simultaneously without sample. All the tubes were kept 
in dark for 30 minutes and the O.D. was measured at 540 nm. 
Cholesterol contents were expressed in terms of mg/g wet tissue. 
5.3 Triglycerides estimation 
Triglycerides estimation was done according to the 
method described by Fletcher (1968). 
100 
Reagents 
1. Alcoholic KOH (0.4% w/v) 
3. 0.05 M sodium metaperiodate (NalO^). 
4. Sodium arsenite: It was prepared by dissolving 2.0 g of 
NaOH and 5 g of arsenic trioxide in 100 ml distilled water. 
5. Chromotropic acid: 500 mg of chromotropic acid was 
dissolved separately in 10 ml distilled water and was added 
to 60% cold H^SO^ solution. It was then filtered through 
glass wool and stored in a dark-coloured bottle in cold. 
6. Standard triglyceride (10 mg/ml): 100 mg of triolein was 
dissolved in 10 ml of chloroform. 
Procedure 
Suitable volumes of standard and lower phase lipid extract 
were pipetted into different tubes. Samples were dried free of 
solvent. 1.0 ml of 0.4% alcoholic KOH was added in all tubes 
except blank tube. In blank tube. 1.0 ml of ethyl alcohol was 
added. It was mixed gently and the tubes were kept in water 
bath maintained at 60-70 °C for 15 minutes. Reaction was 
stopped by adding 1.0 ml of 0.2 NH.SO^ and kept in boiling 
water bath for 10 minutes to remove alcohol. 0.1 ml of NalO 
4 
(0.05 M) was added for peroxidation, Oxidation was stopped 
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by adding 0.1 ml of sodium arsenite. A yellow colour appeared, 
which vanished within few minutes. 8.0 ml fo chromotropic acid 
was added to each tube and kept in boiling water bath for 30 
minutes. Tubes were cooled under tap water and O.D. recorded 
at 570 nm. Triglycerides were expressed as mg/g wet tissue. 
5.4 Separation of different lipid classes by thin layer chromatography 
(TLC) 
Preparation of TLC plates 
Glass plates of dimensions 25 x 12.5 cm were used for 
separating lipid components. Plates were initially cleaned with 
liquid soap. Washed thoroughly with tap water and rinsed 
properly 2-3 times with distilled water and dried in an oven. 
Slurry preparation 
6.0 gm of sillica gel G (with binder) was mixed with 15.0 
ml of distilled water. All the air bubbles were removed before 
applying the slurry on the plate. Plates were coated with slurry 
by spreading it carefully on the plate to make silica gel coating 
of 0.5 mm thickness. Plates were allowed to dry at room 
temperature. Before application of lipid extract plates were 
activated for at least 1 hour at 110 °C 
5.5.1 Separation of Gaiactolipids 
Galactocerebrosides and galactocerebrosulphatides were 
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separated by the method of Gulati et al. (1986). Composition 
of the developing solvent system used was chloroform: methanol: 
ammonia (80:20:0.4 v/v) . Chromatogrpahy chamber of 
dimensions 30 x 17 x 9 cm was made saturated before use. 
20|ig of standard galactocerebroside and galactocerebrosulphatide 
along vsith 20-40 |il of lower phase lipid extract were spotted 
as a 0.5 cm streak at about 2.0 cm above from the base. Samples 
were loaded with a 20 jil microsyringe (TOP) maintaining a 
distance of 1.5 cm between two samples. An indicator dye oil 
red 'O ' (Sigma) was mixed with the samples to observe the 
solvent front. Plates were then placed carefully inside the 
chromatogrpahy tank and were allowed to run for one hour at 
room temperature. Plates were taken out, left for some time for 
the solvent evaporation and then exposed to iodine vapours in 
prepared iodine chamber for 10 minutes. Spots identified by the 
corresponding standard spot were marked clerly by a sharp 
needle. Plates were left at room temperature for the sublimation 
of iodine. Spots and the corresponding blank area were scrapped 
out carefully and quantitatively transferred into separate tubes. 
Galactolipids were eluted from the silica gel by adding 3.0 ml 
of solvent (C:M = 2:1), mixed well and centrifuged at 2,000 
RPM for 5 minutes. 1.5 ml of solvent was taken for Galactose 
estimation from each tube. Cerebroside and sulphatide were 
expressed as rag/g wet tissue. 
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5.5.2 Estimation of Galactose was done according to tlie method of 
Hess and Lewin (1965) 
Reagent 
1. 50% H,SO, 
2. Orcinol-H^SO^ reagent: 110 mg of pure Orcinol crystals, 
weighed directly into the volumetic flask. Dissolved carefully 
in 50% H^SO^ and warmed gently with hot tap water to bring 
Orcinol into the solution. Volume was made upto 50 ml with 
acid and stored in a dark place. 
3. Galactose standard (1 mg/ml): 50 mg of galactose (AR) 
grade dissolved in 50 ml distilled water. 
Procedure 
About 50 ul of lower phase lipid extract and 1.5 ug of 
standard galactose was pipetted into separate tubes. 
Simultaneously a 1.5 ml of aliquot from each separated spot was 
also taken and samples were dried free of solvent. Added 200 
ul of Orcinol-H^SO^ reagent to all the tubes and were buzzed 
vigorously for 1.0 min until the homogenous emulsion was 
formed. A reagent blank was also prepared simultaneously. 
Tubes were kept in metal rack and heated at 100 °C in an oven 
for 30 minutes. Reaction was stopped by placing the rack in ice 
water for 10 minutes and centrifuged at 2,000 RPM for 5 
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minutes. Solution was taken out carefully into quartz 
microcuvette. O.D. was read at 425 nm. Galactolipids were 
expressed as mg/g wet tissue by multiplying the values of 
galactose by a factor of 4.5. 
5.6.1 Separation of Phospholipids 
Five major phospholipids separted were phosphatidylethanolamine 
(PE). phosphatidylcholine (PC), sphingomyelin (SG), phosphatidylinositol 
(PI) and phosphatidylserine (PS). 
These were separated on silica gel G plates using the 
developing system of composition C:M:A (65:25:4% v/v) 
according to the method of Kates et aJ. (1972). 10 jig of 
individual phospholipid standards and 20-40 \i\ of lower phase 
lipid extracts were loaded as a streak above 2.0 cm from base 
maintaining distance of 1.5 cm in between. Plates were kept in 
a presaturated chromatography tank and were allowed to develop 
for one hour at room temperature. Plates were removed and left 
for 30 minutes at room temperature for solvent evaporation and 
then exposed to iodine vapours. Individual spots were identified 
by the corresponding standard spot. Identified spot and the 
corresponding blank areas were scrapped off after iodine is 
evaporated. Phosphorus estimation in all the samples were done 
after acids' digestion. 
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5.6.2 Phospholipid estimation 
Phospholipid estimation was done by the modified 
method of Bartlet (1959) as described by Parker and Peterson 
(1965). Organic phosphorus of phospholipids was converted into 
inorganic phosphorus by the acid digestion procedure. 
Reagents 
1. 30% H,0, (commercial) 
2. 0.4% (w/v) ammonium molybdate 
3. Fiske-Subbarow reagent (ANSA): 0.5 g of 1-amino, 2-
naphthol-4-sulphonic acid was dissolved in 200 ml of freshly 
prepared 15% sodium bisulphite, followed by the addition of 1.0 
g of sodium sulphite. Solution was filtered through glass wool 
and stored in dark colored bottle. 
Procedure 
After separation and identification of individual 
phospholipids, the sillica gel of the corresponding spots were 
scrapped off and taken into separte tubes for acid digestion. 0.5 
ml of concentrated H^SO^ was added to all tubes and were placed 
in heating blocks. Samples were digested initially for 2 hours 
at 250 °C , Tubes were taken out, allowed to cool and then 
added 2-3 drops of 30% Hp^. Tubes were again placed back 
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to heating block and heated for 1 hour at 160 °C . Tubes were 
then cooled under tap \vater and 6.0 ml of ammonium molybdate 
was added to each tube followed by 3.1 ml of distilled water 
to make total 9.1 ml. Finally 0.4 ml of ANSA reagent was 
added, mixed well and kept in boiling water bath for 10 minutes. 
Colour intensity was read at 820 nm against a reagent blank. 
Inorganic phoshorus (Pi) values thus obtained were multiplied 
by a factor 25 to convert Pi into phospholipids. Phospholipids 
were expressed as mg/g wet tissue. 
5.7 Ganglioside estimation 
Total gangaliosides werre estimated as sialic acid content 
by the method of Svernerholm (1957) as modified by Miettennen 
and Takki-Luukkainen (1959). 
Reagents 
1. 0.1 M CuSO, 
2. n-Butyl acetate 
3. 2% (w/v) resorcinol reagent 
4. Working reagent was prepared freshly before use by mixing 
10 ml of resorcinol reagent with 80 ml of concentrted H.,SO 
containing 0.25 ml of 0.1 M CuSO,. Volume was made upto 
100 ml with distilled water. 
5. Blank reagent does not contian resorcinol. 
6. Standard sialic acid (1 mg/ml). 
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Procedure 
Suitable volumes of upper phase lipid extract and standard 
sialic acid (10-100 \xg) were taken for analysis in separate tubes 
and were allowed to dry. 2.0 ml resorcinol reagent was added 
to all tubes except the reagent blank tube where recorcinol blank 
reagent was added. All the tubes were kept in boiling water bath 
for 15 minutes. Tubes were taken out and cooled under tap water. 
4.0 ml of n-butyl acetate was added, mixed vigorously and 
placed in ice eater for 15 minutes. Centrifuged at 3,000 RPM 
for 10 minutes. Colour extracted in the upper solvent phase was 
taken out carefully and O.D. read at 580 nm, Gangliosides were 
expressed as jamoles of sialic acid/g wet tissue. 
7.0 Statistical Analysis 
In order to find out the affect of Glutamate exposure at 
different postnatal ages on the development of rat brain, two way 
analysis of variance technique was used for each brain 
parameters separatly. Bain development parameters were used as 
dependent variables whereas Glu-exposure and postnatal age 
were considered as independent variables. The overall exposure 
and postnal effects were calculated using f-ratio. The 
significance of mean differences between the various sub-groups 
were compared by calculating least significant differences. 
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CHAPTER-OTSTE 
Evaluation of Glutamate Toxicity on tlie Developing Brain : 
A Biochemical Study 
Introduction 
Glutamate and its compounds produce pronounced 
cumulative neuro excitotoxicity and belong to a group of neuro 
exicitotoxicants whose high doses are known to damage a 
number of organs including central nervous system. [Olney, 
1969]. A general concept of the nervous system development is 
that certain animals are born in a relatively mature state of 
neurological competance e.g., horse sheep, guinea pig etc. Where 
as on the other hand there are several others which are borne 
at a time when the development of the brain is not fully complete 
e.g., rat, rabbit, dog, cat. > 
Developmet of the nervous system proceeds in a series of 
interphased stages commencing with the embroylogical events and 
ending with maturity. These stages may be summarised as under: 
(i) Organogenesis and neuronal multiplication 
(ii) A maturation period known as growth spurt during which 
there is axonal growth, dendritic arborisation, 
synaptogenesis, glial multiplication, myelination and 
(iii) A period of generalised growth in size. 
The onset of these various events occur at different 
times (in relation to birth) in different species. As the 
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development of brain proceeds, there is an increased demand of 
energy for conducting a variety of functions. In response to 
energy requirement, there is a rapid increase in the development 
of enzymes linked to the energy metabolism e.g., succinate 
dehydrogenase (SDH), cytochromeC.oxidase (cyt. C) malate 
dehydrogenase (MDH), diaphorase etc. upto 3-5 weeks of post-
natal age. Synaptogenesis is an important event during neuronal 
development which progresses with the simultaneous increase in 
acetyl cholinesterase. Peak rate of DNA biosynthesis coincides 
with the cellular and neuronal multiplication, during early phase 
of brain development. Myelination occurs lastly which is mainly 
associated with the deposition of lipids in the, nervous tissues. 
Davison and Bodding (1968) have stated myelination as a 
vulnerable period in the nervous system development. Myelin 
development is reflected by the parallel increase in the levels 
of myelin associated enzymes i.e.,2',3',-cyclicnucleotide-3'-
phosphohydrolase(CNPase), 5'-nucleotidase (5'N) and carbonic 
anhydrase alongwith the deposition of various lipids. These are 
important biochemical landmarks in the nervous system 
development which are likely to be interrrupted by several 
environmental factors in the developing brain. There are certain 
factors which considerably attribute to the vulnerability of the 
developing brain. They are as follows: 
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1. Neuronal multiplication is generally a prenatal 
phemomenon and the cells under going mitosis alongwith 
the migrating cells are specifically sensitive to toxic 
exposures. 
2. Immature BBB, which is incapable of providing adequate 
protection to the developing brain against the toxicants, 
which is able to reach the fatal brain more easily. Thus, 
it contributes considerably to its damage (Thornberg and 
Moore, 1976). 
3. An additional risk factor is the later develpment of the 
drug metabolizing system, mostly after birth. Thus, it is 
responsible to the more pronounced damages occuring after 
prenatal toxic exposures. 
Several reports and evidences are available, which have 
clearly indicated the highly sensitive nature of the brain 
during the developmental phases and have shown to be 
damaged due to toxic exposures. Minamata disease is the 
one incidence, occurred in the human society after methyl 
mercury poisoning. It adversely affected only the 
prenatally exposed children, which were born of low birth-
weights, whereas their mothers remained unaffected. This 
study has suggested that the dividing cells are more 
susceptible to toxic insults as compared to the adult mature 
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cells (Chang and Annau, 1984). Another report with the 
experimental animals exposed in-utero to a pesticide 
methyl parathion produced to the developing brain which 
were found to be persistent even after at the 28th day of 
postnatal age. It was characterized by observing the 
reduced AChE activity and an increase in choline acetyl 
transferase in brain of exposed pups at days 1, 7, 14, 
21 and 28 after birth (Gupta et.al. 1985). Myelinogenesis 
was found to be hampered significantly in the brain of 
Triethyltin exposed developing rats during postnatal period 
of life, as is evidenced by decreased body weight, brain 
weight, in a myelin yield and in the activity of CNPase 
at 16,21 and 30th day of age. Marked decrease was also 
noticed in cerebroside content by approximately 55% and 
in the activity of CNPase (20%) by the 30 days of age 
in treated rat brain (Blaker et.al 1981). 
Apart from these studies, evidences are also available 
suggesting the direct/indirect effects of toxicants interaction with 
the nervous system development. Kasuya et-al. (1978) have 
demonstrated that cadmium stearate inhibited the outgrowth of 
cerebeller cells of newly born rats growth in vitro and also 
produced degenerating changes at a concentration level of 2.3 
>^  10"^  M. It completely inhibited the out growth of nerve fibres, 
glial cells and fibroblasts. 
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The effects of the toxic exposure during gestation have 
been conducted (Webster 1988; Soler and Law 1990) and on the 
developing neonates (such as Licis et al. 1972, Bhattacharya 
1983; Sikorski et al. 1989), but no such report is available 
regarding the Glutamate neurotoxicity. In this chapter we report 
our findings on the effect of Glumate oral doses on pregnant 
albino rats. 
Therefore, it will be important to evalute Glutamate 
toxicity on the developing brain including the role of essential 
nutrients in Glutamate neurotoxicity. 
Experiment-1 
"Gestational glutamate exposure on brain development: 
a biochemical study." 
Experimental Design 
Dose and Treatment schedule: Pregnant rats were 
exposed to monosodium glutamate (50mg/kg body weight) orally 
from zero day of pregnancy throughout the Gestational period. 
After parturition treatment was stopped and the pups were left 
with the nursing dams. Pups were euthenised at 7, 14 and 21 
days of postnatal age from both control and Glutamate treated 
groups. 
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Results 
Total maternal weight gain (10 animals from each group) 
during gestation period in exposed animals was found to be 
significantly decreased.(C:94+.232vs E: 6.928 ±2.54,25%) as 
compared to the control. Food and water consumption remained 
identical in both groups. The mean of the size in the either of 
these groups did not differ in the exposed group from that of 
the control ones. 
Body and Brain weight 
The growth pattern of body and brain weight of control 
and gestationally Glu-exposed pups is shown in table (1). The 
body weight and brain weight of control pups increased rapidly 
from 7-21 days of postnatal age. Body weight of the exposed 
pups was significantly decreased only at day one (16%) and 
thereafter it was comparable to the control pups. However, brain 
weight of treated pups was found to be significantly reduced at 
day 7 (17%) and at day 14(10%.). 
Development of Enzymes 
The data in table (2) shows the devepolmental 
profile of Na,+K--ATPase, CNPase, 5'-N and AChE in control 
and Glu-exposed pups at the time interval of 7, 14 and 21 days 
of postnatal age.Activity of Na',K"-ATPase increased 
11^ 
Enzymatic Analysis 
The Na*,K"-ATpase, malate dehydrogenase diaphorase, 
succinate dehydrogenase, acetylcholinesterase, 2',3',-cyclic 
nucleotide-3'-phosphohydrolase, 5'-nucleotidase and p-glucor-
onidase were assayed in the control and Glutamate-exposed pups 
at 7, 14 and 21 days of age as described in the materials and 
methods section. 
Table! 
Effect of in-utero Glutamaie exposure on body weight, 
and brain weight in rat pups from 7 to 21 days of postnatal age. 
Parameter 
Bo(^vvei^(g) 
3rain weight(g) 
Group 
C 
E 
C 
E 
Age of pups (days) 
7 
14.^ ±033 
12.95±0.77 
0.72 ± 0.03 
0.60±0.01" 
14 
25.70±020^ 
25.60±0.24a 
1.18±0.03a 
1.06±0.03^* 
21 
44.00 ±87^'' 
43.00±2.0^'' 
1.41±0.0'^ >' 
1.370.05 '^'• 
The values represent the mean ±S.E. of five determination 
Statistical analysis : Two-way ANOVA; 
a,b = significantly different (p<0.05) when compared with day 7 and 14 within 
the same control or Glutamate treated groups 
*,** = significantly different when compared with the corresponding 
controls at p<0.05, p< 0.01 andp<0.001 respectively. 
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Table-2 
Effect of in-utero Glutamate exposure on some neuronal marker 
enzymes during postnatal development in rat brain 
Parameters 
Na-,K--ATPase 
20%21days 
2',3',cyclicnu-
cleotidase -3'-
Phospho-
h>'drolase 
S'-Nucleotidase 
Acetyl choline-
sterase 
Group 
C 
E 
C 
E 
C 
E 
C 
E 
Age of pups (days) 
7 
0.030±0.003 
0.033±0.004 
0.057±0.005 
0.08ftH).003 
0.023±0.001 
0.030*0.002 
8528+3.30 
99.17+3.22 
14 
0.077i^.003^ 
0.081±0.005^ 
0.634±0.023^ 
0.449+0.03= '^" 
(-29%) 
0.029+0.001 
0.019^ "+0.001 
(-32%) 
114.03+ 3.5P 
102.61+6.40 
(-13%) 
21 
0.11+0.002^'' 
0.088+0.004^"* 
(-20%) 
1.136+0.023'^ '' 
0860+0.039"''-'" 
(-24%) 
0.134+0.005"^ " 
0.039+0.003ab~ 
(-70%) 
133.60+3.16^ 
116.66+2.85,''"' 
Table : Activities expressed as n moles of substrate hydrolysed / min / 
mg protein 
Values represent the mean + S.E. of 5 determinations 
Statistical analysis done by Two-way ANOVA 
a,b = significantly different (p <0.05) when compared with day 7 and 
14 respectively within the same control or Glutamate treated groups. 
**,***,= Significantly different when compared with the corresponding 
control at p <0.01 andp<0.001. 
The values in parenthesis denotes the percent change from the 
control values. 
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Table-3 
Effect of in-utero Ghttamate exposure on marker enzymes of • 
energy metabolism and f5-glucoronidase in rat brain 
Enzymes 
Malate 
dehydro-
genase 
Diaphorase 
Succinate 
degydro-
genase 
|i-glucoro 
nidase 
Group 
C 
E 
C 
E 
C 
E 
C 
E 
7 
0.674±0.20 
0.624±0.029 
123.222±4.138 
99.160±6.5 
(-20%) 
0.146±0.011 
0.117±0.006 
(-20%) 
0.459.±0.024 
0.568+0.300 
(+24%) 
Age of pups (days) 
14 
1.105±0.029' 
0.986±.034' 
94I50±3.734' ' 
77.206+2.512^"* 
(-18%) 
0.178+0.011 
0.090+0.005'** 
(-49%) 
0.600+ 0.035* 
0.701±0.300 
(+17%) 
21 
1.55210.064*-'' 
1.165±0.114*-''"* 
(-25%) 
75.469+1.963'^" 
52 900+3.901*-'''"* 
(-30%) 
0.197+0.011*-'' 
0.140+ 0.007a,b*** 
(-27%) 
0.770+0.032* 
1.023+0.038''*** 
(+33%) 
Table 3: Activites expressed as n-moles of substrate hydrolyzed/min /mg 
protein 
Values represent the mean + S.E of five-determinations + n moles of 
phenolphthalein liberated / hour/ mg/ protein 
Statistical analysis done by Two-way ANOVA 
a,b = Significantly different (p<0.05) when compared with day 7 and 14 
respectively within the same control or Glutamate treated group. 
*'**'***= Significantly different when compared with corresponding control 
atp<0.05, p<0.01 andp<0.001 respectively 
The values in parenthesis denotes the percent change from the 
control. 
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continuously from 7-21 days in both control and treated pups. 
But the activity was found to be significantly decreased at days 
21 (20%) in the Glutamate exposed group when compared to the 
age matched control groups. Similarly, AChE also increased from 
7-21 days in control groups. However, same pattern was not 
followed in the exposed individuals and the decreased activity 
of AChE was found at day 21 (13%) in Glu-treated group. The 
activity of CNP-ase and 5'-N were found to be very low at day 
7 with a sharp elevation (11 folds and 5 folds respectively) at 
day 14 followed by a further increased at day 21 in control pups. 
However, gestational Glu-exposure have resulted in the 
significantly decreased activity of CNP-ase by 29% and 24% 
wheres the activity of 5'-N was inhibited by 32% and 70% at 
days 14 and 21 respectively as compared to the control pups 
of the same age. 
Table (3) shows the development of 
mitochondrial enzymes, i.e, SDH, MDH and diaphorase along 
with the neurotoxic marker enzyme P-glucoronidase. SDH and 
MDH increased continuously from day 7 to 21 in control pups. 
Activity of MDH was significantly inhibited at day 21 (25%) 
but SDH was noticed to be very sensitive enzyme and remained 
inhibited throughtout from 7-21 days of age in the Glu-treated 
group. Diaphorase activity was found to be maximum at day 7 
and decreased thereafter at 14 and 21 days in control pups. Glu-
121 
exposure resulted in the reduced diaphorase activity at all the 
tested time intervals. Increased activity of b-glucoronidase in 
the brain of Glutamate treated pups was found during postnatal 
period of development as a result of gestational exposure. 
Discussion 
The Glutamate has been reported to cross the placental 
barrier and enters the fetal circulation during prenatal period of 
life and via mother's milk it also reaches to the neonates during 
postnatal period. Thus, the fetuses and the neonates both are 
vulnerable to the toxic effects of this excitatory amino acid. As it 
has been stated earlier that the development of brain starts 
prenatally and proceeds postnatally upto a certain period of time, 
the present study was aimed to assess whether this low amount of 
Glutamate entering the fetal and neonatal brain could directly or 
indirectly interfere with the important biochemical events occurring 
during the brain development. 
Results of the present investigation indicate that the 
effect of maternal Glutamate exposure on brain weight is in 
agreement to results of metal exposures as earlier report by 
Sorrel and Graziano (1990) which may be due to fetal Glutamate 
accumulation or fetal since deprivation (Record, 1987). Marked 
deficit in the brain weights of Glutamate exposed rats suggests 
the potentiality of Glutamate to cause CNS toxicity by altering 
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the normal brain functioning. This study emphasizes the risk of 
prenatal Glutamate exposure, its effect on the important 
biochemical processes associated with the neurogenesis and the 
brain development. 
Most of the enzymes studied in the brain were found 
to increase rapidly upto day 21 of age with the development of 
various cellular and subcellular fractions reflecting the increased 
functional activity of brain. The multiple role of Na%K^-ATPase 
in the active transport of various nutrients, in cell permeability, 
generation of ADP, nerve impulse transmission and in many 
other biological functions are well documented. It seems to be 
inhibited by Glutamate exposure in different tissues. Glutamate 
exposure during gestation period have resulted in the significant 
decrease in the activity of Na",K*-ATPase (day 21) in the 
developing brain as compared to the control rats of the same 
age. The present study experiments have also demonstrated the 
Glutamate-induced inhibition of ATPase in the Synaptosomes and 
microsomes of the rat brain. It seems that in the present study 
the Glutamate interacts with the phosphorylation step of the over 
all Na%K^-ATPase reaction and inhibition in the enzyme 
activity was found to be restored by the thiol compounds such 
as -cysteine, dimercapto succinic acid and dithiothretol. It 
impieties the possible binding of Glutamate to the SH group 
of enzyme resulting in the reduced activity. Thus, the observed 
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inhibition in the Na^,K"-ATPase activity in the brain of 
Glutamate-exposed developing pups may lead to the functional 
impairment of synaptic transmission w^hich resumble with the 
results of the low level exposure metal induced neurotoxicity 
(Cooper et.al., 1984) along with various neuronal activities. 
Certain mitochondrial enzymes related to energy 
metabolism (MDH, SDH and diaphorase) were also included in 
this investigation, since during development there is a high 
requirement of energy and any toxic exposure at this stage might 
interact with the proper development of these enzymes. Data of 
the present study demonstrates that Glutamate exposed pups 
were not able to attain the normal levels of the studied 
mitochondrial enzymes in comparison to the control ones. 
Gestational Glutamate exposed resulted in the significantly 
reduced activities of SDH and diaphyseal continuously from 7 
to 21 days of postnatal age, Glutamate has been reported to 
inhibit a variety of mitochondria l functions. SDH and 
diaphorase continuously from 7 to 21 days of postnatal age. 
Glutamate has been reported to inhibit a variety of mitochondrial 
functions. 
Diaphorase is a flavin-linked enzyme involved in the 
oxidation of pyruvate to acetyl CoA. Its biological significance, 
isolation and purification in the nervous tissue have been 
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reported by Kuonen et al. (1988). The ontogenic pattern of this 
enzyme was found to be retarded in exposed rats indicating the 
possible interaction of Glutamate at this step of energy 
metabolism. An important step in the TCA cycle is the 
conversion of L-malate into oxaloacetate which is catalyzed by 
MDH. The extensive requirement of NAD for oxidative 
phosphorylation is partially fulfilled by MDH. Glutamate 
exposure resulted in the significantly decreased MDH activity 
at day 21 of age. Since, the development of brain is dependent 
on the adequate energy supply for various essential biochemical 
functions during development which were found to be imparired 
in Glutamate exposed rats and may lead to the multidimensional 
affects and abnormal brain growth. 
AChE present at the cholinergic nerve endings is a good 
neuronal marker enzyme. In the present study its activity was 
found to be reduced at day 21 in treated rats indicating that 
prenatal Glutamate-exposure may cause retardation in the 
ontogenic development of cholinergic synapses. It may be 
infered from the present study that Glutamate may directly 
inhibit AChE activity or it may be reduced because of the 
Glutamate interaction with the voltage gated Ca^^ entry into the 
presynaptic nerve endings and subsequently inhibiting the 
release of acetylcholine. Further, this study also emphasizes the 
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risk of prenatal Glutamate toxicity on the myelination process 
in the growing rat brain. The two enzymes CNPase and 5'-N were 
found to be highly sensitive to Glutamate exposure. Marked 
inhibition in the development of these myelin associated 
enzymes was observed at day 14 and 21, which coincides with 
the onset of myelination in rat brain indicates the possible 
interaction of Glutamate with this important event occurring 
during nervous system development. It seems possible that 
Glutamate absorbed once can't be easily excreted from the brain 
and it is capable of producing damage even after the withdrawal 
of the exposure which may persist during adulthood. This study 
provides a biochemical basis for Glutamate-induced 
neurotoxicity and the vulnerability of developing brain to the 
gestational and lactational Glutamate-exposure leading to 
insomnia, dementia, and loss of memory, cell death and 
Parkinson's disease. 
Experiment!: "Thymidine Kinase activity and DNA-
biosynthesis in Glutamate exposed pups during brain 
development". 
Experimental Design 
Dose and treatment schedule 
Rats were exposed orally to monosodium glutamate (50 
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gm/kg body weight) from zero day of pregnancy throughout 
gestation and lactation period (up to 21 days after parturition). 
Control as well as Glu-exposed pups were sacrificed at 7,14 and 
21 days of postnatal age for various estimations. 
Parameters : DNA- synthesis, DNA, RNA and protein contents, 
and thymidine kinase activity as described in the materials and 
method section. 
Results: After having been exposed to 50mg/kg body weight 
glutamate, the water consumption was observed to be almost 
identical in control and Glu-treated groups, although, it was 
considerably higher during the lactation period in respect to the 
gestational intake. 
Body and brain weight: Gestational and lactational Glutamate 
exposure resulted in a significant retardation in body and brain 
weight at each time interval as compared to the control pups. 
Maximum decrease in body weight (26%p<0.01) and brain 
weight (14%, p<0.01) was noticed at 21 day of postnatal age 
(Table 4). 
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Effect of Glutamate exposure in the development of thymidine 
kinase, DNA biosynthesis and nucleic acid contents: 
DNA biosynthesis development of thymidine kinase 
activity DNA, RNA and protein contents in brain of control as 
well as glutamate treated pups at 7,14 and 21 days of postnatal 
days as shown in table (5). DNA and RNA contents increased 
significantly with the increase in age from 7-21 days in both 
the groups, however, the level of increases in DNA content of 
the treated pups was significantly lesser compared to the age 
matched control group. Synthesis of DNA was also reduced in 
the brain of Glutamate exposed pups as evident by 11% reduction 
in [ ^H]- thymidine incorporation at 7 days 67% at days 14 and 
53 percent reduction at 21 days of age. 
The activity of thymidine kinase increased 
considerably from 7-14 days of age (0.581 - 0.736 n moles/ hr/ 
mg protein) and was almost levelled at 21 days of age in control 
pups. Pups in the experimental group showed significant 
decreased activity of thymidine kinase at all the tested time 
intervals, with a maximum reduction at day 21 (28% p<0.01) 
of age compared to the control pups. The total content of protein 
was comparable in both the groups which increased considerably 
from day 7 to 21st of age. 
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Table-4 
Ejfect of gestational and lactational Glutamate exposure on the body and brain 
weights of rat pups from 7-21 days of postnatal age. 
Parameters 
Body weight (g) 
Brain weight (g) 
Group 
C 
E 
c 
E 
Age of pups (days) 
7 
16.48 ±0.55 
13.98 ±0.79 
(-17%) 
0.90 ± 0.05 
0.8 ±0.04 
(-10%) 
14 
29.68 ± 0.94« 
22.47 ±0.62^  
(-24%) 
1.40 ±0.07* 
1.18±0.05'-**' 
(-13%) 
21 
37.98 ±1.89^'' 
27.98 ±2.02 '^'"' 
(-26%) 
1.70 ±0.06^^ 
1.453 ±0.07*^ '** 
(-14%) 
The values represent the mean + S.E. of 5 determinations 
Statistical analysis done by Two- way ANOVA 
a, b = Significantly diflFerent (p<0.05)when compared with day 7, and 14 age within 
the same control or Glutamate treated group. 
*,**,*** = Significatly dijSemt from the respective control atp<0.05, P<0.01 
andp<0.001 respectively. 
The values in parenthesis denotes the percent change from the control 
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Table 5 
Ejfect of gestational and lactational Glutamate exposure on DNA 
biosynthesis, Thymidine kinase, DNA, RNA and protein content in rat pups 
during postnatal brain development (7-21 days). 
Parameters 
[3H] Thymidine 
incaqjoration into 
DNA cpm mg/DNA 
Thymidine kinase 
moter/protein/hr 
DNA/mg/gwet 
RNA /mg/g wt. 
Protein/mg/gwet 
Group 
C 
E 
C 
E 
C 
E 
C 
E 
C 
E 
Age of pups (days) 
7 
1648±71 
1469±24* 
(-11%) 
0.579±0.023 
0.480±0.012 
(-17%) 
1.061±0.012 
0.964±0.027 
0.923±0.036 
1.783±0.051 
38.30±0.64 
36.67±0.80 
14 
29093±1177* 
9459±1000' 
(-67%) 
0.734±0.03* 
0.6230.011''* 
(-15%) 
1.234±0.046' 
1.041±0.056 
2.435±0.099 
2.28.±0.044 
42.28±1.08 
40.52±0.44 
21 
22402±919*-
10342±1654''^ ** 
(-53%) 
0.773±0.047' 
0.552±0.022" 
(-28%) 
1.233±0.044 
1.148^ .^024""* 
2.923±0.062 
2.772±0.038 
49.9]±1.200 
9 46.97i0.50'-*' 
The values represent the mean ± S.E. of five determinations 
Statistical analysis done by Two- way ANOVA; 
a,b = Significatly different (p<0.05) when compared with 7 and 14 days of age 
within the same control or glutamate treated group. 
*,**,*** = Significantly different fi-om the respective control at p< 0.05, 
p< 0.05 and p<0.001 respectively. 
Tie values in paranthesfs demotes fte percent change from fte controls. 
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DISCUSSION 
In the present study, maternal exposure of Glutamate 
in drinking water throughout gestation and lactation period 
resulted in a significant growth retardation in their rats as 
evident by body weight reduction. Similarly the Glutamate also 
produced significant decrease in the brain weight of rats as 
« 
compared to the controls. 
Since the active phase of brain development lies 
between 7-21 days of age in case of rats during which majority 
of microneurons are formed, differentiate and migrate to their 
final distinction. Therefore, any type of excitotoxic exposure at 
this critical stage of development may interact with the 
proliferating stem cells resulting in a smaller number of cells 
undergoing mitosis (Thornberg and Moore, 1976). In the present 
study Glutamate-exposure resulted in the significant reduction 
in the content of DNA and its synthesis as evident by significant 
reduction in [^H]-thymidine incorporation and the activity of 
thymidine kinase at 7, 14 and 21 days of age in respect to the 
age matched controls. Glutamate has been reported to suppress 
PH]-thymidine incorporation into regenerating liver as well as 
in the kidney and tests of suckling mice (Friedman and Staub, 
1976; Cihak and Inou, 1979). In vitro studies with Glutamate 
have also reported reduced cell division in cultured 
131 
adrenocortical and thymus cells, indicated by the decreased 
uptake of [^H]-thymidine by these cells (Gawarski and Sharma, 
1978; Nishiyama and Nakamura, 1984). Observed reduction in 
brain weight of Glutamate exposed pups in this study may be 
a consequence of depression in cell multiplication due to 
decreased DNA synthesis. However, a possibility of cell 
degeneration owing to continuous presence of the high doses of 
glutamate in the brain may also be a contributory factor for such 
changes. 
Maximum changes in DNA synthesis and in the activity 
of thymidine kinase coincide with the zinc deficiency in the 
brain of Glutamate exposed pups. Incorporation of deoxy 
thymidine into DNA involves its phosphorylation first to deoxy 
thymidine-5'-monophosphate which is catalyzed by thymidine 
kinase and then to deoxy thymidine triphosphate. Thymidine 
kinase is a metallozyme and requires adequate concentration of 
zinc for its activity which have been reported to be inhibited 
in Zn-deficient state resulting in the less number of cells 
(Fujioka and Lieberman, 1964). The prolonged exposure of 
Glutamate may also be one of the factors responsible for causing 
a decrease in the activity of thymidine kinase and subsequently 
reduced incorporation of [^H]-thymidine into DNA in the brain 
of Glutamate exposed rats. Further, depressed activity of 
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thymidine kinase has also been found in Glutamate-exposed 
embryos resulting in an overall decrease in DNA synthesis 
(Webb and Samarawickrama, 1981). Glutamate interfere with 
nucleic acid synthesis in a variety of ways. It is therefore 
suggested from the present study that Glutamate may directly 
or indirectly affect the development of brain and zinc play a 
crucial role in aggravating its effect on the DNA synthesis. 
Further, the results of the present study have also 
revealed significant accumulation of Glutamate in the brain of 
exposed rats. Maximum Glutamate accumulation was noticed at 
day 7 which remained almost identical at days 14 and 21 of age, 
since lactational exposure contributes to very little transfer of 
Glutamate to the neonates, a significant amount of Glutamate 
accumulated in brain may be a result of Glutamate exposure 
during gestation period). 
It may be concluded from the present study that 
maternal Glutamate-expo sure during pre and postnatal periods 
causes retardation in brain growth which may be due to the 
significant reduction in DNA synthesis and thymidine kinase 
activity in developing brain. 
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CHAPTER-TWO 
Effect of Prenatal and Postnatal exposure, of Monosodium 
glutamate on the regional development of biogenic amines in 
the CNS of Albino Rats 
INTRODUCTION 
For the vast majority of all known proteins, Glutamate 
(Glu) is the major amino acid. As an essential link in 
intermediary metabolism, it is also largely present in its free 
form in animal and plant tissues. 
As the sodium salt of Glutamate has become a widely 
used food ingredient, there is hardly any product that could 
more justifiably be called a food ingredient. Unfortunately, 
monosodium glutamate (MSG) is considered to be a "synthetic 
food additive or a chemical seasoning". 
Glutamate is also a major excitatory neurotransmitter in 
adult central nervous system (CNS). (Watkins and Evans, 
1981; Fonnum, 1984; Shank & Aprison, 1988). Regions in 
which Glutamate is thought to be the primary mediator of fast 
excitatory synaptic neurotransmission include the visual cortex, 
hoppocampus, cerebellum and spinal cord (Collingridge and 
Lester, 1989). This supposition is supported by experimental 
evidence indicating that Glutamate meets many of the criteria 
required to be called a neurotransmitter. (Werman, 1966). 
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These criteria include: 
(i) the presence of Glutamate in synaptic vesicles 
(ii) an increase in Glutamate in perfusates from activated 
synapses and 
(iii) the presence of an inactivating mechanism. 
Glutamate is sequestered by an ATP-dependent mechanism 
(Naito and Ueda, 1983) in synaptic vesicles at concentrations 
estimated to be between 60 mM-200 mM (Riveros et al., 1986; 
Burger et al., 1989). These levels are about 6-10 times greater 
than those present in the cytoplasm. Glutamate is also released 
from synaptosomes by depolarization (Nicholls and Sihra, 
1986; Sanchez-Prieto et al., 1987) and from hippocampal 
slices by depolarization or afferent pathway stimulation in a 
Ca^ ^ dependent manner (Nadler et al., 1976; Wieraszko and 
Lynch, 1979; Spencer et al., 1981). Finally, glia possess 
electrogenic glutamate uptake systems dependent on Na" and 
K^ (Henn et al., 1974; Barbour et al., 1988). Though the 
existence of a synthetic enzyme is another requirement to be a 
neurotransmitter, the source of the glutamate in synaptic 
vesicles is unclear (Nicholls and Attwell, 1990). 
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Demonstration of a candidate neurotransmitter meeting the 
above criteria may be technically difficult, therefore, two 
additional criteria have been identified as being critical. These 
are: 
(iv) the candidate neurotransmitter must mimic the effect of 
afferent fibr stimulation. 
(v) the candidate neurotransmitter and the true 
neurotransmitter must have the same pharmacological 
properties. (Werman, 1966). 
Much evidence of this kind exists to support the 
hypothesis that Glutamate is a neurotransmitter at excitatory 
synapses in the vertebrate CNS (Mayer and Westbrook, 1987; 
Collingridge and Lester, 1989). 
Therefore, it becomes clear that glutamate (being 
excitatory neurotransmitter) should have some link to the 
alterations in the levels of other neurotransmitters as the 
contrasting pharmacology and the ionic dependence of 
glutamte uptake carriers int he vesicle membrances and in the 
plasma membrane explain how glutamate can function as a 
neurotransmitter, and why the extracellular glutamate 
concentration rises to neurotoxic levels in brain anoxia. 
C:\pni5\pm5\farooque\diagram.pm5 
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In the present study, the effect of glutamate on the 
levels of other neurotransmitters (biogenic amines) such as 
norepinephrine, dopamine and 5-hydroxytryptamine 
concentrations in different regions of central nervous system 
(cerebrum, cerebellum, brain stem and spinal cord) has been 
studied for justifying the neuroexcitotoxic nature of 
monosodium glutamate (MSG). 
Experimental Design Pregnant rats were exposed to 
monosodium glutamate (MSG) from zero day of pregnancy 
throught gestation and lactation period till dessication of the 
delivered pups. After weaning (21 days of postnatal age) 
growing pups were exposed to glutamate up to 60 days. 
Ten rats each from control and glutamate treated group 
were sacrificed by decapitation at 21,45,60 and 150 days of 
postnatal age for the estimation of biogenic amines in the 
central nervous system (cerebrum, crebellum. Brain stem and 
spind cord) of albino rats. Spontaneous locomotor activity 
(SLA) was also monitored simultaneously in control and 
glutamate treated group as described in the materials and 
method section. 
Results: Body and brain growth pattern 
Body weight increased rapidly from 21 days to 
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60 days of age in the control group (50 to 150g). The body 
weight gain at 150 days of age as compared to that at 60 days 
was increased from 150 to 250 gms. Monosodium glutamate 
administration resulted in the marked deficit in the body 
weight gain (30 to 120 gms) by the end of 21st day of age. 
By the end of the 60 days of age glutamate - administered rats 
were having less body weight as compared to that of the 
control ones. Brain weight increased significantly from 21st to 
60 days of age and attained about 121% of weight by the end 
of 60 days as Compared to the weight gain at 21st day in 
control groups whereas the glutamate treated rats showed a 
marked reduction in the weight gain at 21 days in (11%) 
45days (11%) and 60 (30%) days EAAs rats showed about 
15% redyction in brain weight by the end of the experiment 
(150 days of postnatal age). 
Spontaneous Locomotor Activity (SLA): 
Monosodium glutamate treatment resulted in increased 
motor activity in 21 days old rats as compared to the controls. 
However, continuous glutamate-exposure let to the mark 
reduction in the later stages i.e, days 45 and 60 compared to 
the corresponding controls. 
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Effect of pre-and postnatal glutamate exposure on the 
regional development of biogenic amines in the CNS of 
albino rats 
Norepinephrine (NE) 
Fig (1),(2),(3) and (4) show the developmental profile 
of Norepinephrine (NE) in different regions of CNS of albino 
rats from 21 to 60 days of postnatal age. Norepinephrine level 
incresed significantly from 21 days to 60 days of postnatal 
age in different regions of CNS of albino rats. Glutamate-
exposure on the other hand resulted in marked alterations in 
NE levels in various regions of CNS at all time intervals. At 
21 days of age, NE levels were found to be significantly 
increased in cerebellum and spinal cord by 32% and 21% 
respectively compared to the control rats of the same age. 
Marked reduction in NE levels were observed in all the 
regions at 45 and 60 days except spinal cord which showed 
increased level at day 45 by 19%. Similarly NE level were 
also depleted at 60 days of age in all regions. 
Dopamine (DA): 
Fig (5), (6), (7) and (8) show the developmental pattern 
of DA in different regions of CNS of albino rats from 21 to 
60 days. The regional contents of DA were increased 
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significantly from 21 days up to 60 days of age with the 
development of CNS. The normal developmental profile was 
not followed by the glutamate exposed rats. The DA levels 
were significantly decreased in cerebrum, spinal cord and 
Brain stem by 35%, 23% respectively in treated rats at 21 
days of age. Glutamate-exposure further resulted in retarded 
development of DA in cerebrum (19%) Brain stem (20%) and 
spinal cord (27%) regions at 45 days of age. Significantly 
decreased level of Dopamine were noticed in all the regions 
except carebum which showed 42% increase in DA levels at 
60 days of age. Cerebelum was found to be less sensitive to 
glutamate where DA levels were altered only at 60 days of 
age. 
5-Hydroxytryptamine (5- HT): 
The regional development of 5- HT is shown 
in Fig (9) ,(10) ,(11) and (12). As the CNS development 
takes place, levels of 5-HT found in serotonergic neurons also 
increased significantly in different regions of CNS of albino 
rats. The 5-HT contents were considerably higher at 60 days 
of age in comparison to the contents found at day 21st in all 
the regions of CNS of albino rats. This developmental pattern 
was alterd in the glutamate exposed rats. The 5-HT levels 
were altered initially at 21st day of age in cerebrum by 22% 
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1.0_ 
0.8 
0.6 
0.4 
= Control group 
Experimental group 
21 45 60 
Age (in days) 
Cerebrum 
Fig (1): Effect of pre-and postnatal glutamate exposure on the 
levels of Norepinephrine in cerebrum 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 
21 and 45 of age within the same control or glutamate exposed 
group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.01(**). 
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1= Control group 
H= Experimental group 
Age (in days) 
Brain stem 
Fig (2): Effect of pre-and postnatal glutamate exposure on the 
levels of Norepinephrine in Brainstem 
Values are represented as Mean +. S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the day 21 
and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.01(**). 
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= Control group 
§ = Experimental group 
21 45 
Age (in days) 
Cerebellum 
60 
Fig (3): Effect of pre-and postnatal glutamate exposure on the 
levels of Norepinephrine in Cerebellum 
Values are represented as Mean ± S.E of 5-determination. 
statistical analysis done by TWO-WAY ANOVA • 
a,b,c = statistically significant (p<0.05) when compared with the days 
21 and 45 of age within the same control or glutamate exposed 
group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.001(***). 
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1-i 
1.2 
1.0 
0.8 
0.6 
0.4 
0.2 
=^ Control group 
= Experimental group 
JL 
45 
Age (in days) 
Spinal cord 
60 
Fig (4): Effect of pre-and postnatal glutamate exposure on the 
levels of Norepinephrine in Spinal cord 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 
21 and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.01(**). 
\= Control group 
^ ^ = Experimental group 
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1.0 
0.8_ 
0.6 
0.4 
0.2 
21 45 
Age (in days) 
Cerebrum 
60 
Fig (5): Effect of pre-and postnatal glatamate exposure on the 
levels of Dopamine in Cerebrum 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
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I 1= Control group 
^ S = Experimental group 
21 45 
Age (in days) 
Brainstem 
60 
Fig (6): Effect of pre-and postnatal glutamate exposure on the 
levels of Dopamine in Brainstem 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 21 
and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.01(**), and p<0.001(***). 
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T^ 
Control group 
Experimental group 
21 45 60 
Age (in days) 
Cerebellum 
Fig (7): Effect of pre-and postnatal glutamate exposure on the 
levels of Dopamine in Cerebellum 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 
21 and 45 of age within the same control or glutamate exposed 
group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*). 
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\ \= Control group 
= Experimental group 
21 45 
Age (in days) 
Spinal Cord 
60 
Fig (8): Effect of pre-and postnatal glutamate exposure on the 
levels of Dopamine in Spinal Cord 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 
21 and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.001(***). 
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1= Control group 
^ y = Experimental group 
21 45 60 
Age (in days) 
Cerebrum 
Fig (9): Effect of pre-and postnatal glutamate exposure on the 
levels of 5-Hydroxytryptamine in Cerebrum 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 21 
and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.01(**). 
'1 
1.4 
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= Control group 
= Experimental group 
Age (in days) 
Brain stem 
Fig (10): Effect of pre-and postnatal glutamate exposure on the 
levels of 5-Hydroxytryptamine in Brain stem 
Values are represented as Mean +_ S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 21 
and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.001(***). 
= Control group 
WM = Experimental group 
1 5 2 
21 45 60 
Age (in days) 
Spinal cord 
Fig (11): Effect of pre-and postnatal glutamate exposure on the 
levels of S-Hydroxytryptamine in Spinal cord 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 21 
and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.01(**). 
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1-4. 
1.2, 
1.0 
0.8_ 
0.6^ 
0.4_ 
0.2_ 
\= Control group 
mm '^m= Experimental group 
60 21 45 
Age (in days) 
Cerebellum 
Fig (12): Effect of pre-and postnatal glutamate exposure on the 
levels of 5-Hydroxytryptamine in Brain stem 
Values are represented as Mean + S.E of 5-determination. 
Statistical analysis done by TWO-WAY ANOVA 
a,b = statistically significant (p<0.05) when compared with the days 
21 and 45 of age within the same control or glutamate exposed group. 
Asterisk denotes statistically significant when compared with the 
corresponding controls at p<0.05(*) and p<0.01(**). 
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compared to the control values at this time interval. Glutamate 
exposure resulted in differential changes in varrious brain 
regions at 45th and 60th days of age. It was observed that 
cerebrum, cerebellum and Brain stem showed enhaced level of 
5-HT at 45th day whereas spinal cord showed significantly 
decreased level of 5-HT. By the end of 60 days of postnatal 
age glutamate administration produced marked reduction in 5-
HT levels of cerebrum, spinal cord and Brain stem with 
significantly high level in cerebellum. 
Discussion:-
The data of the present investigation provide a complete 
picture of the regional development of the three important 
central neurotransmitters (NE, DA and 5-HT) with the 
development of brain. Glutamate administration during 
prenatal and postnatal periods of life alter the ontogenic 
pattern of the neurotransmitters in different regions of centre 
nervous system (cerebrum, cerebellum. Brain stem and spinal 
cord) of albinorats. In the present study neurochemical 
alternations were found to be associated with the behavioural 
disorders particularly in the spontaneous locomotor activity in 
the glutamate treated rats. 
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It is evident that the glutamate administration at early 
stages of life resulted in the increased locomotor activity in 
suckling rats which may be due to the significantly altered 
levels of NE and 5- HT in different regions of CNS at 21 
day of age. Broitraent and Donaro (1971) have reported earlier 
that the brain NE levels are associated with the motor 
performance behaviour. Involvement of serotonergic neurons in 
the locomotor activity have also been evidenced earlier (Greek 
and Kelly, 1976; Rastogi and Singhal 1976). Glutamate 
administration induced behavioral excitation in the exposed 
rats which on repeated exposure of glutamate resulted in the 
significantly decreased locomotor activity with the increasing 
age. 
The present study indicates the relative sensitivity of 
different regions of CNS of albino rats towards glutamate 
induced toxicity and its long lasting impact on the steady state 
levels of the three neurotransmitters. Results of the present 
investigation indicate decrease in the levels of 5-HT which may 
be due to the glutamate (MSG) induced deviatioin in the 
biosynthetic ability of serotonin in the affected regions by 
altering the enzymes Tryptophan hydroxylase which acts at the 
first step of 5-HT synthesis as reported by Rastogi et al. (1977) 
or by activating the metabolizing enzyme monoamine oxidase 
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which seems to be altered in glutamate exposed conditions. 
Since the sevotonergic neurons in the brain stem are involved 
in learning and sensory perception it is suggested from the 
present study that glutamate induced reduction in the 5-HT 
levels in brain stem region may be responsible for the learning 
disability memory loss and delay in sensory stimulus. 
It seems from the present study that the glutamate -
exposure during the critical periods of brain development 
ratards the brain growth. It produces retardation in the 
ontogenic profile of regional neurotranmitters. It is further 
indicated that the developing featus/neonate is at the higher 
risk of exposure because the developing brain is at the more 
vulnerable to the various toxicants by interacting with the 
important neurophysiological and neurochemical events. These 
neurochemical changes may be responsible to produce 
behavioural deficits of the early stage of postnatal life which 
may have long-lasting functional/behavioural disorders during 
adulthood. 
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CHAPTER-THREE 
Ontogeny of antioxidant Defense System in Rat Brain in 
Response to Gestational and lactational Glutamate 
Exposure 
Introduction 
Free radicals are highly reactive intermediates formed 
in many biochemical processes which are capable of attacking 
the polyunsaturated fatty acids (PUFA) of the membrane lipids. 
This oxidative damage of membrane lipids is known as lipid 
peroxidation. Malondialdehyde (MDA) is a short chain product 
of peroxidation reactions which may also interact with the other 
important cellular constituents e.g. proteins, nucleic acids and 
phospholipids mainly 
RNH2 + OCH-CHj-CHO+H^N-Rl 
R-N=CH-CH=CH-NH-Rj+2H20 
(Schiffs base) 
Thus, free radicals-induced lipid peroxidation disrupts 
the membrane integrity and biological functions, which may 
lead to cell death. Role of free radicals have been implicated 
in the neurodegenrative disorders, during ageing and in 
neurotoxicity of certain chemicals (Tappel, 1973: Halliwell and 
Gutteridge, 1985: Halliwell, 1989: Lebel and Bondy, 1990). 
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Several defense mechanisms are being operated within 
the biological system and provide adequate protection against 
these types of oxidative damages under normal conditions. 
However, but under certain circumstances, e.g., the effectiveness 
of these protective mechanisms may be decreased or completely 
hampered, resulting into abnormal physiological functions. 
Xenobiotics is one of the example of such influence. 
The defense mechanism is a close combination of 
biological antioxidants, enzymes and glutathione dependent 
systems. Vitamin E (a-tocopherol) is recognized as a "chain-
breaking" antioxidant which inhibits lipid peroxidation by 
allowing free radicals to abstract a hydrogen atom from the 
hydroxyl group of Vitamin E rather than from polyunsaturated 
fatty acid. Thus, breaking the chain of free radical reactions and 
the tocopheryl radical is relatively neuroactive species, which 
may be regenerated to Vitamin E in the presence of vitamin C 
(Ascorbic acid). Important enzymatic free-radical scavenging 
system includes: superoxide dismutase (SOD) which exists in 
two forms. A cytosolic Cu-Zn SOD and a mitochondrial Mn-
SOD. SOD scavenges the superoxide radical (O^) and forms H O 
SOD 
O ,+0 ,+2H' > H,0,+0, 
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Catalase is another enzyme, which is responsible for 
dealing with large amounts of H ^ , generated during cellular 
and subcellular reactions. 
2 H , 0 , Catalase ^ 2H3O+O, 
Glutathione peroxidase (GPx) which provides the 
most vital defense mechanism against lipid peroxidation in the 
cell is a system dependent on reduced glutathione (GSH). It 
reduces fatty acid hydroperoxides to stable hydroxylipids, 
preventing lipid hydroperoxide breakdown. GSH utilized by GPx 
is converted to GSSG, which is again recycled back to GSH 
by an enzyme Glutathione Reductase (GR). Glutathione also 
serves as an intracellular sulphahydryl buffer and plays a 
significant role in protecting thiol containing enzymes in their 
active reduced form (Orrehenius el al., 1983). 
Since brain contains large amounts of Polyunsaturated 
fatty acids (PUFA) and receives 20% of the cardiac output of 
blood resulting into high oxygen tension, it may be highly 
susceptible to free radical mediated damage (Halliwell and 
Gutterdige, 1985; Tayarani et al, 1989). Development of the 
antioxidant substances in the glial cells (component of BBB) 
occurs prior to the development in neurons (Savolainen. 1978; 
Raps et al, 1989). It provides first line of defense against toxic 
assault. However, toxic moieties capable of successfully 
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traversing this glial cell barrier, may cause damage to the 
developing neurons. Levels of the antioxidant enzymes are 
known to be altered under abnormal physiological conditions. 
High levels of serum Mn-SOD have been reported to be 
associated with the neuromuscular disorders (Taniguchi et al., 
1991) and in patients with neuroblastoma (Kawamura et al., 
1982). 
Glutamate seems to interfere with the antioxidant 
defense machinery in various organs and enhance peroxidative 
damage to the biomembranes. Glutamate-exposure seems to 
produce damage to the growing brain, by inhibiting the regional 
levels of antioxidant enzymes e.g. SOD, GR, GPx, CAT and the 
levels of glutathione. 
It is clearly indicated from the present study that 
glutamate has a potential to cause toxicity to the nervous system 
and free radicals may be the common mediators of neurotoxicity 
but no such report is available in this regard so far as glutamate 
neuro-excitotoxicity is concerned. Therefore, the present study 
was undertaken to elucidate whether or not exposure during the 
very early period of life could interfere with the proper 
development of antioxidant machinery in immature rat brain, 
which is quite vulnerable to toxic exposures as compared to the 
adult brain. Such alterations might play a critical role in the 
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outcome of toxicity and may also be responsible for the more 
pronounced damages reported in developing nervous system. 
Experimental Design 
Pregnant female rats were exposed orally to 
monosodium glutamate (MSG) from zeroth day of pregnancy 
throughout the gestation period and the neonates were exposed 
lactationally by exposing nursing mothers to the same dose of 
Glu. upto 21 days after parturition. Both control and Glu-
exposed pups were killed at day 1,7,14 and 21 of postnatal age. 
Ten brains from the each group were used at 1 and 7 days of 
age, two brains were pooled to make total five samples per group 
for analysis. Five brains at 14 and 21 days of age were processed 
individually in an identical manner. Lipid peroxidation, 
glutathione (GSH) and total sulphahydryls (SH) were 
quantitated at 1,7, 14 and 21 days of age. Further, glutathione 
peroxidase (GPx), glutathione reductase (GR), superoxide 
dismutase (SOD) and catalase (CAT) were also assayed at the 
same time intervals in control and glutamate treated rats 
according to the procedures described in the Materials and 
Methods Section. 
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Results 
Effects of pre-and postnatal Glutamate (MSG) exposure on 
body and brain weights 
The glutamate exposure to dams did not produce any 
significant change in their body weights. However, exposure 
to offsprings through their mothers significantly reduced body 
weight (33%, p<0.001) and brain weight (22%, p<0.001) of 1-
day old pups, compared to their counterparts in control group. 
The brain and body weights of the pups of both the groups 
showed a significant rise at 7, 14 and 21 days of age. However, 
the values did not differ significantly in the Glu exposed pups 
during these periods (Table 1). 
Effect of pre-and postnatal Glu exposure on LPO, GSH and 
total sulphahydryl contents in developing brain 
The measurement of malonedialdehyde in terms of 
thiobarbituric acid reactive substances (TBARS) following one-
hour incubation showed a significant increase in lipid 
peroxidation at all the studied time intervals. A highest increase 
of 34.5% (p<0.001), compared to corresponding controls was 
observed at 21.day of age. Developmental pattern of GSH 
contents showed a large variations at different ages, levels 
observed at 1 day of age increased significantly at 7 days of 
age and later on decreased at day 14 before it increased again 
on day 21 to a level which even su^^assed its previous highest 
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levels obtained at 7 days of age, The high level of glutamate 
exposure significantly decreased the concentration of GSH in 
one day-old rats (17%, p<0.01) and increased at 7(13%, p 
<0.05), 14 (22%, p.< 0.05) and 21 (8%, p <0.05) days of age 
compared to their corresponding controls. The analysis of total 
SH contents of brain at different ages revealed a rapid increase 
from 1st day of life to 14'*" day. The exposure to Glutamate 
significantly increased total brain SH levels by 30% (p<0.01) 
in 1-day old and 12% (p<:0.05) in 7-day-old rat pups. The SH 
concentration at 14"' and 2P' day of life in glutamateglutamate-
exposed groups remained unaltered in comparison to the age 
matched control pups (Table 2). 
Effects of pre-and postnatal Glu-exposure on brain enzymic 
antioxidants 
Glu-exposure through mothers increased the SOD 
activity in 1-day-old pups (45%. p<0.01), followed by a decrease 
at 7 days (27%, p< 0.01), 14 days (25%, p<0.001) and 21 days 
(26%, p<0.01) of life compared to the controls of the same age. 
The developmental pattern of GPx showed a peak activity on 
1'' day of life which substantially decreased to around one-
fourth at later time periods. A comparison with control values 
showed almost double activity (IO40/0, p< o.OOl) in Glu exposed 
Table 1 
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Effect of pre-and postnatal Glu exposure on body and brain 
M'eights of albino rats at different postnatal ages 
4ge (days) 
1 
7 
14 
21 
Group 
C 
E 
C 
E 
C 
E 
C 
E 
Body Weight (g) 
5.97+0.19 
4.02+0.286'*' 
(-33%) 
12.32+0.203" 
11.30+0.345^ 
21.20+0.3 5 2'''*' 
20.20+0.646^''' 
36.60+1.575^-^'= 
33.50+1.59'''''= 
Brain Weight(g] 
0.35+0.004 
0.245+0.005 
(-22%) 
0.664+0.02P 
0.645+0.020" 
1.114+0.013"*' 
1.115+0.012"^ 
1.302+0.015"^-^ 
1.315+0.015"*' = 
Values represent the mean + S.E. of ten determinations. 
Statistical analysis done by TWO-WAY ANOVA. 
a,b,c = Statistically significant (p<0.05) when compared with day 
1, 7 and 14 within the same control of Glu-treated group. 
" •= Statistically significant at p< 0.001 when compared with 
the corresponding control. 
The values in parenthesis denotes the percent change from the 
controls. 
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Table 2 
Effect of pre-and postnatal Glutamate exposure on LPO,GSH and 
TSH of developing brain of albino rats at different postnatal ages 
Age 
(days) 
1 
7 
14 
21 
G r^oup 
C 
E 
C 
E 
C 
E 
C 
E 
Lipid peroxidation 
(nmoles of TEARS/ 
hr/g tissue) 
48.±1.59 
82±5.96" ' 
(+73%) 
37±1.46« 
48 i l . 29^*" 
(+30%) 
36±120« 
44±2.39«' 
36±3.98'' 
165±15.67^''''='*" 
(+354%) 
Glutathione 
{\i moles/g tissue) 
0.382±0.008 
0.317+0.014" 
(-17%) 
0.628+.0.016'' 
0.709±0.025«' 
(+13%) 
0.383±0.013'' 
0.468+.0.016«'''' 
0.796±0.005«'''''= 
0.863±0.023»'''''' 
(+8%) 
Total sulphahydryls 
{\i moles/g tissue) 
0.499±0.034 
0.647±0.019*' 
(+3%) 
0.843+.0.024'' 
0.944±0.035«'' 
(+12%) 
1.203±0.007''''' 
1.236+0.026^-'' 
1,367±0.019«'''= 
1.4 3 5±0.02 6 *•''= 
Values represent the mean ± S.E. of ten determinations. 
Statistical analysis done by TWO-WAY ANOVA. 
a,b,c = Statistically significant (p<0.05) when compared with day 
1, 7 and 14 within the same control of Glu treated group. 
• '"•"= Statistically significant at p<0.05, p<0.01 and p<0.001 
when compared with the corresponding controls. 
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Table 3 
Effect ofpre-andpostnatal Glutamaie exposure on SOD, GPx, CAT and 
GR activities in developing brain at different postnatal ages 
Age 
(days) 
1 
7 
14 
21 
Group 
C 
E 
C 
E 
C 
E 
C 
E 
Superoxide 
dismutase 
(units/mg protein) 
0 417+0 022 
0 603+0 046" 
(+45%) 
0 356+0 023 
0 260+0 012a," 
(-27%) 
0 247+0 OOS"-^  
0 185+0 009'''"" 
(-25%) 
0 267+0 015" 
0 197+0 0014'" 
(-26%) 
Glutathione 
peroxidase 
(nmolesofGSH 
Oxidised/min/mg 
protein) 
80+5 94 
163+5 90"" 
(+104%) 
227+5 21-
207+6 42'• 
(-9%) 
64+2 22" 
48+5 94'''• 
(-26%) 
58+3 48^'' 
43+1 94'-''" 
(-26%) 
Catalase (nmoles 
ofH203 
Decom./min/m 
g protein 
5 5+0 249 
6 64+0 147"" 
(+31%) 
9 83+0 244' 
15 73+0 475'-"" 
(+60%) 
7 97+0 314'" 
11 24+0 887' ' '" 
(+40%) 
8 98+1 80a 
14 94+0 975'-'" 
(+66%) 
Glutathione 
reductase 
(nmoles of 
NADPH 
Oiidiscd/min/mg 
protein 
32 6+1 21 
41 6+2 16" 
(+28%) 
29 6+1 63 
35 4+1 50'"" 
(+20%) 
8 0+0 51-^ " 
10 1+0 44'" 
(+27%) 
1 7+0 15^"' 
2 5+0 21'-"'" 
(+50%) 
Values represent the mean + S.E. of ten determinations. 
Statistical analysis done by TWO-WAY ANOVA. 
a,b,c = Statistically significant (p<0.05) when compared 
with day 1, 7 and 14 within the same control of Glu-
treated groups. 
•'•*•"•= Statistically significant at p<0.5, p<0.1 and p<0.001 
when compared with the corresponding control. 
The values in parenthesis denotes the percent change from 
the controls. 
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animals at day one of age; however, a significant decrease was 
noticed on 7th (9%, p< 0.05). W^ and 21" day (26%, p < 0.05 
and 0.01) of life. The activity of catalase in control group 
showed lowest levels at 1-day which increased by 7"" day and 
remained almost stationary throughout the experimental period. 
Glu exposure elevated catalase activity at all the studied time 
intervals, with a maximum alteration observed at 21 days of age 
(66%, p< 0.01) compared to the age matched controls. The 
ontogenic pattern of GR revealed a maximum activity at day-
one of age which decreased rapidly after that. The activity 
observed at day 21 of age was found to be decreased by 19 folds 
compared to the activity at day one of age in control group 
Glutamate exposure resulted in the marked increase in the 
GR activity at day-1 (28%, p< 0.01) (20%, p< 0.001), 14 (27%, 
p< 0.05) and 21 (50%, p< 0.01) day of postnatal age. 
Discussion 
The results of the present study demonstrated that 
exposure to high doses of Glutamate in pregnant rats, produced 
alterations in the levels of various enzymic and non-enzymic 
antioxidative defense system. It also induced LPO potential in 
the developing brain of progenies from mothers which were 
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exposed during gestation and lactation period. One-day-old pups 
of Glu-exposed group showed reduction in their body and brain 
weights. It indicated that glutamate-exposure could be more 
severe during the gestation and lactation period. A normal 
weight gain by body and brain, seven days after birth, suggested 
an impressive recovery during lactation period. 
Lipid peroxidation potential in brain of Glu-exposed 
pups was found to be significantly enhanced at all the time 
intervals of the study, with a maximum alteration at 21st days 
of age. The developmental pattern of brain GSH concentration 
in our studies showed the considerable fluctuations, which may 
reflect the need of this thiol molecule at different stages of 
development. Glu-exposure produced a biphasic effect on GSH 
levels, it decreased the levels at one-day of age and increased 
significantly at rest of the time intervals. Taniguchi and Inoue 
(1986) have reported ontogenic changes in the metabolism and 
transport of glutathione in rats. The levels of total thiol groups 
were increased significantly in 1 and 7 day old animals. GSH 
depletion and a decreased ratio of GSH/GSSG have been reported 
daily for 30 days to the weaned rats. The discrepancy in the 
GSH levels of brain in response to Glu challenge may be arising 
due to the lack of a sequential analysis as most of the studies 
-ported one-time-point analysis. It is quite possible that the 
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changes in GSH levels may depend upon the duration of Glu-
exposure and their internal dose. The observation of an elevated 
levels of GSH in later periods i.e. 7, 14 and 21 days of age, 
following an initial decrease at 1-day of age may be resulted 
from an onset of some compensatory mechanism in the body. 
GSH, is a ubiquitous suphydryl tripeptide, which plays a vital 
role in a variety of physiological processes and is an important 
factor responsible for the maintainance of cellular redox 
potential. Thiol compounds including GSH have been shown to 
protect the issues against glutamate induced damages. 
The decreased activity of SOD and GPx in present study 
at 7, 14 and 21 days of age are in accordance with previous 
reports on various organs including brain on exposure to other 
toxicants in rats (Shukla et ah, 1987; Shukla et al., 1989). The 
elevated levels of these enzymes in 1-day-old rat brain may be 
as a result of their induction in response to some kind of -
oxidative stress produced by glutamate exposure. Increased 
accumulation of glu with the time of exposure, a concentration 
of Glu may be reached in brain which would be inhibitory to 
these enzymes by directly interacting with enzyme molecules. 
On the same pattern, SOD was found to decrease in various 
regions of Glu treated rat brain. Glu exposure was found to 
elevate the activities of catalase and GR at all the studied time 
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intervals. The differences in the route and dose of exposure 
along with the age of the animals may be responsible for the 
present results. It is also possible that most of the effects 
observed here in the brain at different ages of postnatal life. 
It may be representing a reflection of the recovery process going 
on in response to the direct toxic insult after gestational Glu 
exposure and to a lesser extent during lactational period, is 
indicated from the present findings that it could be related to 
an enhancement of the detoxication process following Glu-
exposure. 
The present study suggests that Glu exposure induces 
oxidative stress in brain which may be responsible for a variety 
of CNS dysfunctions following Glu intoxication 
Therefor, it may be concluded from the present study 
that high levels of glutamate exposure during gestational and 
lactational period may produce changes in antioxidant defense 
system and induce LPO in brain of Glu exposed pups during 
its critical period of development which may have some serious 
implications in later life. 
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CHAPTER-4 
Influence of High-level monosodiura glutamate exposure 
on the Developmental Profile of Brain lipids. 
Introduction 
An important event during nervous system 
development is associated with the rapid depostion of lipids, 
termed as myelination. In most of the species, e.g., rat, rabbit, 
mouse and human, it is a postnatal phenomenon which occurs 
after the neuronal multiplication and synaptogenesis. 
Myelination occurs at about 10-12 days after birth and continues 
upto 70-90 days in rats. Myelin is formed by the oligodendrocyte 
cells in central nervous system (CNS) and by Schwann cells in 
peripheral Nervous system (PNS) which wraps around nerve 
fibers and provides insulation, thus helping in a speedy nerve 
impulse transmission. The major lipids found in the nervous 
system are Cholesterol, Phospholipids, galactocerebroside 
(CER) and galactocerbro-sulphatide (SUL) and gangliosides. 
Lipid composition of the developing brain differs considerably 
from that of adult brain (Cuzner and Davison, 1969; De souza 
and Horrocks, 1979; Dallal and Einstein, 1969; Wells and 
Dittmer, 1967). Since the rate of cerbroside deposition has been 
rupurted to be parallel to the myelin development, it is an 
excellent marker of nervous system development. Sulphatide is 
deposited at higher rate during early 3-5 weeks of age. However, 
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the ratio of sulphatide/cerebroside gets lowered with the 
maturation of myelin. The peak rate of biosynthesis of these 
glycolipids was reported to be at 22nd day of postnatal life in 
case of rats. Gangliosides are largely associated with the neurons 
plasma membrane. Maximum biosysthesis of gangliosides is 
achieved at about day 12 after birth in rats. It is clearly indicated 
that the development of brain proceeds with the marked changes 
in lipid metabolism which plays an important role in the 
development of structural and functional brain lipids. Any type 
of toxicity occurring during this vulnerable period might 
interface wath the proper develpment of brain resulting in the 
impaired neuronal maturation. 
Experimental design 
Sperm positive female rats were divided into two 
group (i) control and (ii) experimental having 10 animals per 
group. Rats of the experimental group were exposed to 
monosodium glutamate (MSG) (50mg/kg body wt.) orally from 
zero day of pregnancy throughout the gestation period. After 
parturition, the neonates, the neonates were exposed lactationally 
by continuing the exposure of the nursing dams to Glutamate 
for further 21 day. The exposure continued, in certain cases by 
Glutamate mixed drinking water to weaved rat pups upto 45 days 
of their age. 
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Lipid Analysis 
Five pups from each control and Glutamate treated 
group were euthenized at 15, 21,30 and 45 days of age. Brains 
were taken out and proceeded for lipid extraction and estimation 
as described in methodology section. Development of total 
l ipids, cholesterol , total tr iglycerides, galactocerebroside, 
sulphatide, total gangliosides and five major phospholipids were 
followed at different time intervals. All the estimations were 
done as described in the materials and methods section. 
Results 
Effect of Pre-and Postnatal Glutamate Exposure on Body and 
Brain Weights: 
The high-level EAA's administration during prenatal 
and postnatal periods of life did not alter the pattern of body 
weight and brain weight of the rat pups from 15 to 45 days of 
age as compared to the control as shown in table 1. 
Effect of Prenatal and postnatal Glutamate treatment on the 
Developmental Profile of Brain Lipids 
Glutamate exposure during early periods of brain 
development resulted in a significant oxidation in the total brain 
lipids at the tested time itervals i.e., 15, 21 , 30 and 45 days 
of age, compared to the respective age-matched control group. 
At 45 days of age, total lipids were decreased by 15% in the 
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treated pups. The levels of total triglycerides (TG) were found 
to be maximum at 15 days of age and were maintained during 
the later periods of brain development in the control pups. 
However, remarkable increase in TG levels was noticed in the 
Glu-exposed pups at days 15 (12%, P<0.05) of postnatal life 
compared to the counterpart controls (Talbes-2). The 
Profile of cholesterol and total ganglio side in shown 
in Table-2 An age dependent increases in the concentration of 
cholesterol was recorded as a consequence of brain development. 
Glu was found to decrease the cholesterol levels significantly 
at each interval of analysis with a maximum reduction observed 
at day 30 of age (16%, P<0.05). On the other hand gangliosode 
levels were elevated significantly, the Glu- exposed pups at 21 
(25%P<0.05) 30 (17%,P<0.05) and 45 (23% P,<0.05)days of age 
compared the respective control. 
The data in Table-3 further showed the developmental 
pattern of the two important galactolipids i.e CER and SUL in 
the rat brain from 15 to 45 days of age. The concentration of 
CER and SUL increased markedly from day 15 to 45 in the 
control pups whereas in the Glu-intoxicated individuals such an 
increase was slower and exhibited significantly lower - levels 
compared to respective controls from days 21 onwords .By the 
45 days of age, these animals showed 43 % reduction in CER 
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(p<0.01) levels and 37% reduction (p<0.05) in SUL levels as 
compared to controls. 
The postnatal development of five different 
phospholipids i.e PE, PC SP, SI and PS in control and Glutamate • 
exposed rats in presented in Table-4. The levels of PE were 
found to be significantly elevated at all the tested time intervals 
from 15 to 45 days of age with a maximum increase at 15 days 
of age (36% p<0.01) in the Glu-exposed group. Whereas the 
levels of PC increased significantly only at days 21 (14°/b 
p<0.05) followed by a significant decrease at 30 (14% p<0.05) 
and 45 (19% p<0.05) days of age in response to pre-natal and 
postnatal Glutamate exposure. The levels of other three 
phospholipids i.e SPG, PI and PS in the treated group showed 
a significant reduction in SPG (21% p0.05), PI (34% p<0.01) 
and PS (43% p<0.05) after the continuous Glutamate exposure 
at 45 days of age. 
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Discussion 
Formation of myelin is a critical step in the maturation of brain, 
which is associated with corresponding increase in the concentration of 
several lipid constituents. The active phase of myelin development ranges 
from 15 to 45 days of postnatal life in case of rats (Norton and Poduslo, 
1973). The data of the present investigation reveals the chemical 
impairment in the composition of brain lipids in response to high level 
Glu administration resulting in a 15% decrease in total lipid content by 
the 45 days of age in respect to controls. The observed decrease in the 
total lipid contents may be due to the decreased deposition of certain major 
lipid components. A decreased content of total brain lipid was also reported 
at 22"'' day of age after pre- and postnatal Glu administration (50 mg/ 
kg,orally, at 3"*, 10^ and 17*^  day) which may ultimately cause structural 
and functional damage to the myelin membrane and thus to the CNS 
dyfunction. 
It seems from the present study that the cholesterol levels were 
significantly reduced at very initial stage of myelination i.e. day 15 of age 
(9%, p <0.05) which further decreased with the period of exposure, 
resulting in the 15% reduced levels by the age of 45 days in the treated 
individuals. A remarkable decrease in the cholesterol levels during 
postnatal development (20 to 60 days) was reported in the myelin fraction 
of protein mahiourished mice (Yusuf e/ al. 1981). In the whole brain and 
cerebral region of the Glutamate exposed rats chronic exposure of 
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Glutamate (50 mg/kg body Weight, orally for 135 days) to albinorats 
resulted in highly reduced levels (74%) of brain, cholesterol. The present 
investigation revealed a remarkable depletion in the levels of CER and 
SUL continuously from day 21 upto 45 days of age. An inhibition in the 
galactolopid (CER and SUL) accumulation in rat brain in response to 
various toxiants e.g. methyl mercury, triethyl lead, inorganic lead, triethyl 
tin and in undernourished mice, during the active phase of brain 
development have been reported (Grundt and Neskovic, 1980; Blaker et 
a]., 1981; Stephens and Gerber, 1981; Yusuf e? al, 1981). Gulati et al. 
(1986) have demonstrated a marked decrease in glycolopid levels in 
weanling rat brain exposed postnatally to cadmium (2 mg /kg. i.p.). The 
analysis of various phospholipids in the present investigation showed that 
the two phospholipids, PE and PC were altered following an early 
exposure, whereas the SPG, PI and PS were impaired only after a long-
term Glutamate exposure, at 45 days of age. The observed enhancement 
in the PE levels at all the studied time intervals suggests the involvement 
of some compensatory mechanism or is a result of gests the involvement 
of some compensatory mechanism or is a result of metabolic disturbance 
in response to pre and postnatal Glutamate exposure. Therefore, it can be 
said that Glutamate exposure to the developing brain may alter the activities 
of important enzymes of lipid metabolism, thus produce changes in the 
chemical composition of brain lipids. The noticeable increase in the 
ganglioside contents from 21 to 45 days of age and an initial increase in 
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the total triglycerides at the day 15 of age in Glutamate exposed rats, 
may be resulted from these metabolic alterations, however, further 
experiments are required to elucidate the exact mechanism of these 
alterations. 
The results of the present investigation imphcate the interactions 
of Glutamate with the ontogenic profile of important lipid constituents of 
rat brain during the active phase of myelin development, at 50 mg/kg 
body Wt. dose level. Therefore, it may be concluded from the present 
study that Glutamate-induced disturbance in the chemical make-up of the 
brain lipids which are the structural backbone of the biological membranes 
and are the basis of the structural integrity for the proper neuronal 
functions, maybe one of the possible reasons underlying the long lasting 
neurotoxic potential of Glutamate, particularly following exposure at early 
life. Furthermore, it can be deduced from the present investigation that 
Glutamate becomes "excitotoxic" when the rats are subjected to its high 
level exposure and result in cell death, dementia loss of memory. Insomnia 
and Parkinson's disease. 
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SUIVIIVIARY 
Glutamate is mainly excitatory amino acid but some 
reports are available in the li terature indicating its potential 
toxicity to the nervous system. Insomnia is a very common 
f inding in the Glutamate exposed individuals and the 
behavioral deficits, like loss of memory, learning disability, 
poor I .Q. performance along with distrubed motor and 
perceptual abilities in the prenatally and post natally exposed 
rats have been reported. 
The development of nervous system starts during the 
late period of gestational exposure and continues upto the 
early period of lactational exposure which is also known as 
the vulnerable period. Therefore, the present study was 
conducted to evaluate the effect of Glutamate exposure on the 
brain development The present investigation also deals with 
some of the important biochemical aspects to explore the ill 
effects of Glutamate especially on the developing brain. This 
dissertation begins with a general introduction followed by the 
review of literature and materials and methods section. The 
experimental part is divided into four chapters. Each chapter 
is framed into the headings of introduction, experimental 
designing, results and the discussion part. The overall 
discussion of this study ,s covered .n the general d.scuss.on 
section. 
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Chapter 1 presents the developmental profile of some 
important enzymes of energy metabolism, like succinate 
dehydrogenase (SDH), malate dehydrogenase (MDH) and 
diaphorase; Na', K^- ATPase which is associated with the 
active transport of ions and other biomolecules, 
acetylcholinesterase (AChE) a cholinergic synaptic marker 
enzyme: 2'3'-cyclic nucleotide-3'-phosphohydrolase (CNPase) 
and 5'-nucleotidase (5'N) are the two enzymes which are 
associated with the myelinogenesis and a lysosomal enzyme (3-
glucuronidase in the brain of control and gestationally and 
lactationally Glutamate-exposed (50 mg/kg body weight 
orally) rat pups at 7, 14 and 21 days of postnatal life. The 
data obtained after this study showed marked decrease in the 
activity of SDH, MDH and diaphorase in the Glutamate 
exposed pups. SDH and diaphorase were found to be most 
sensitive to Glutamate and were altered continuously from 7th 
to 21st day of age compared to their counterpart controls. As 
a result of gestational and lactational exposure to Glutamate, 
activity of Na",K^-ATPase and AChE were significantly 
decreased at day 21 of age. A marked reduction in the 
ontogenic development of the two myelin associated enzymes 
CNPase and 5'-N was observed at the early stage of the onset 
of myelinogenesis i.e. at day 14 and remained decreased at 21 
days of age. Glutamate caused significant elevation in the 
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activity of p-glucoronidase at all the studied time intervals. 
Glutamate was found to be accumulated in significant amounts 
in the brain of rat pups. However, the levels were found to 
be higher at day 7 of age and remained almost identical at 
day 14 and 21 of age after gestational Glutamate exposure. 
The second part of this chapter deals with the effect 
of Glutamate (50 mg/kg body weight orally) on the DNA 
biosynthesis, its synthesis related enzyme thymidine kinase 
(TK), contents of DNA, RNA and protein, after gestational 
and lactational exposure. Gestational and lactational exposure 
to Glutamate resulted in the significant retardation in the body 
and brain weights of pups at 7, 14 and 21 days of age as 
compared to controls. DNA biosynthesis in the brain was 
inhibited to a greater extent at days 14 and 21, as evident by 
the decreased uptake of [^HJ-thymidine, in comparison to the 
control pups. TK was decreased at days 7, 14 and 21 as 
compared to the control pups. Reduction in DNA-biosynthesis 
have led to the decreased levels of DNA from 7 to 21 days 
of life following Glutamate exposure. 
Chapter II emphasizes the risk of gestational/ 
lactational and postanatal Glutamate exposure (50 mg/kg body 
weight upto 60 days of age) on the regional development of 
three major central neurotransmitters (I) Norepinephrine (NE), 
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(ii) Dopamine (DA) and (iii) 5- hydroxytryptamine (5-HT) in 
different regions of central nervous system i.e. cerebrum, 
cereblum, brain stem and spinal cord. The levels of NE, DA 
and 5-HT alongwith the spontaneous locomotor activity (SLA) 
in control and Glutamate-exposed rats were monitored at day 
21, 45 and 60 of age and after the cessation of Glutamate 
treatment for 90 days i.e. at 150 days of age. Results of this 
study exhibited significant decrease in body and brain weights 
throughout the Glutamate treatment period. The present study 
indicated the relative sensitivity of different regions of CNS 
of albino rats towards toxicity and its long lasting impact on 
the steady state levels of the three neurotransmithers. Results 
of the present investigation indicated decrease in the levels of 
5-HT which may be due to the Glumate exposure induced 
deviation in the biosynthesis ability of serotonin in the affected 
regions by altering the enzymems Tryptophan hydroxylase or 
by activatiang the metabolising enzyme monoamine oxidase 
which seems to be altered in glutamate exposed condition. It 
seems from the results of the chapter that the glutamate 
exposure at the critical periods a brain development retards the 
brain growth due to the altered levels of three important central 
neurotransmitters i.e. 5-HT, Dopamine, and Norepinephrine 
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Chapter III deals with the effect of Glutamate 
exposure (50 mg/kg body weight orally) during gestational and 
lactational periods on the development of brain free radical 
scavenging system. The enzymes linked with this system are 
glutathione reductase (GR), Glutathione peroxidase (GPx), 
superoxide dismutase (SOD) and catalase (CAT), were studied 
alongwith total glutathione (GSH) levels, total sulphahydryls 
(TSH) and lipid peroxidation (LPO) at the ages of 1,7 14 and 
21 in the brain of control and Glutamate exposed rats. The 
data revealed that LPO increased significantly in the treated 
pups at all the studied time intervals, with a maximum increase 
at day 21 of age. Developmental pattern of GSH showed 
marked variation at different postnatal ages and the Glutamate 
administration increased the GSH levels at day 1st of age, 
which decreased later on at days 7 and 14 followed by a 
marked elevation again at 21 day of age as compared to 
controls. Total Sulphahydril levels increased at 1 and 7 days 
only in response to glutamate exposure and were comparable 
to the control values at 14 and 21 days of age. Activities of 
SOD, GPx were increased in 1-day old pups, whereas inhibited 
significantly at 7, 14 and 21 days of age following Glutamate 
treatment. GR and CAT were found to be elevated at all the 
studied time intervals from 1-21 days of age after Glutamate 
administration. 
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Chapter IV shows the developmental profile of major 
brain lipids in response to pre and postnatal Glutamate 
exposure (50 mg/kg body weight). Lipids were quantitated at 
15, 21, 30 and 45 days of age in control and experimental 
animals. This study was attempted to understand the possible 
biochemical lesions responsible for a variety of neurological 
disorders in human and experimental animals. Since, lipids are 
the integral components of the neuronal membranes, any 
alteration in the lipid contents may lead to the derangement 
of the neuronal membranes and may cause functional 
impairment in the neurophysiological activities governed by the 
Central Nervous System. Results of the present investigation 
indicated an age dependent increase in the concentrations of 
Brain lipids in the control as well as in the treated group. 
However, their rate of deposition was found to be slower in 
Glutamate exposed pups which resulted in the reduced levels 
of total brain lipids as compared to controls. Glutamate 
exposed pups revealed a reduction in the cholesterol levels 
at all the studied time intervals, continuously from 15-45 days 
of age with a maximum decrease at 30 days of age in 
comparison to the controls. Levels of 
galactosylcerebroside(GalCER) and galactosylcerebrosulphatide 
(GalSUL) were decreased markedly at days 21, 30 and 45 of 
age in response to Glutamate administration. The analysis of 
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different phospholipids showed an elevated levels of 
phosphatidylethanolamine at all the time intervals from 15 to 
45 days of postnatal life. Whereas, the levels of 
phosphatidylcholine increased only at day 21 and decreased 
later on at days 30 and 45 of age. The levels of total 
triglycerides were significantly increased only at 15 days of 
age and were comparable to the control values later on. 
A continuous increase in the levels of total 
gangliosides, quantitated as N-acetylneuraminic acid, were 
noticed from day 21 onwards in the pre- and postnatally 
exposed rats. 
Experimental findings of this dissertation implicate 
that the Glutamate-exposure to the fetus/ neonates and the 
growing rats affects the normal brain development by 
interacting with the various important events of brain 
development. During the process of active brain development 
there is a high demand of energy. Some enzymes associated 
with the energy metabolism were inhibited in the brain of 
Glutamate exposed pups, this may affect a variety of neuronal 
functions. Inhibition in the DNA-biosynthesis may be the 
possible cause of retardation in body and brain weight in the 
Glutamate-treated pups. It may further be concluded that the 
behavioural deficits like change in the locomotor activity is 
195 
related to the alterations in the levels of neurotransmitters. The 
changes in the levels of neurotransmitters after Glutamate-
treatment were found to be regio-specific and could not be 
recovered completely after the cessation of the Glutamate 
exposure. It implicates the persistent long-term effect of early 
Glutamate-exposure. Interaction of Glutamate with both the 
enzymic and non-enzymic antioxidant defense system with 
increased lipid peroxidation led to the conclusion that the free 
radicals may be the initiators of Glutamate-induced 
neurotoxicity. Altered chemical composition of brain lipids 
may be due to the possible interaction of Glutamate with the 
lipid metabolism and the retarded ontogeny of myelination 
associated enzymes indicates that Glutamate impairs the myelin 
development and thus effects the maturation of brain. 
Furthermore, it also seems to be obvious that early exposure 
to Glutamate may cause improper development of various 
cellular and neuronal components needed for structural 
maintenance and proper functioning of central nervous system. 
It may therefore be concluded that the Glutamate 
exposure to the developing fetus/neonate and growing animals 
has a potential to impair the development and maturation of 
brain. Glutamate-induced biochemical and behavioural 
alterations may persist for a long time thereby suggesting that 
an early exposure may produce some serious implications in 
later life. 
